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ABSTRACT
Title of Dissertation: DELIVERY OF DNA AND RECOMBINANT 
INFECTIOUS BURSAL DISEASE VIRUS 
VACCINES IN OVO
Lenita Moura, Doctor of Philosophy, 2004
Dissertation directed by: Professor Vikram N. Vakharia
Center for Biosystems Research, and VA-MD Regional 
College of Veterinary Medicine
Infectious bursal disease virus (IBDV) remains a serious problem for commercial 
broiler producers throughout the world. An in ovo delivery system for plasmid DNA 
vaccines was evaluated by studying parameters, such as the route of delivery (air cell vs 
amniotic cavity), transfection reagent (IFA+DMSO vs polyethylenimine), dose of 
plasmid DNA (1 to 100 µg/egg), and the nature of humoral immune responses.  An 
optimal response was detected when embryos were inoculated with 60 µg of plasmid 
DNA.
This system for in ovo delivery was used to determine the efficacy of a plasmid 
DNA vaccine against IBDV in 18-day-old embryos. The DNA vaccine expresses the 
polyprotein VP2-VP4-VP3 of IBDV. SPF and fertile broiler eggs with maternal 
antibodies were vaccinated and challenged against IBDV-STC. Two groups of birds (SPF 
and broilers) received a booster immunization with baculovirus expressed-proteins of 
IBDV. The DNA vaccine had no detrimental effect on hatchability or first week post-
`
hatch survival. In ovo vaccination generated detectable humoral immune responses as 
measured by ELISA. Antibody response was significantly enhanced two weeks post the 
IBDV-protein boost. Broilers vaccinated with plasmid DNA or IBDV-protein boost 
exhibited partial protection against IBDV-STC strain, whereas, vaccinated SPF chicks 
were not protected and exhibited severe microscopic lesions after challenge.  
A second approach in the control of IBDV used a recombinant attenuated vaccine 
administered in ovo to 18-day-old embryos. The vaccine was genetically tailored to 
protect from challenges in the field against classic and variant strains of IBDV. SPF and 
fertile broiler eggs were vaccinated and used to evaluate protection against IBDV-STC 
challenge. A full dose of the vaccine consisting of 5.6x103 pfu was administered to SPF 
and commercial broiler embryos. In addition, a half dose containing 2.3x103 pfu was 
injected in SPF embryos. The vaccine generated high antibody titers in chickens 
vaccinated with either dosage. All vaccinated groups were protected against mortality. 
The vaccine did not cause bursal damage and fully protected SPF chicks vaccinated in 
ovo with 2.3x103 pfu and broiler embryos that received a full dose of the recombinant 
vaccine. The vaccine had no effect on hatchability or first week survival in either broilers 
or SPF birds, even when high doses were administered.  
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1.1. In ovo vaccination
Today, in ovo vaccination against Marek’s disease virus (MDV) is a worldwide 
practice in broiler production. Indeed, in ovo injection is practiced in 30 countries around 
the world, and in more than 85% of all broilers in the U.S.
The embryonated egg is an immobile target that can be easily accessed by high-
speed automated equipment, such as the commercial egg injection system used for the 
vaccination of the embryo. Birds vaccinated in ovo for Marek’s disease (MD) exhibit 
better performance in the field than birds vaccinated at hatch due to reduced stress 
associated with the elimination of manual handling during vaccination. Vaccine delivery 
is aimed into the amniotic cavity of the embryo. Thus, in ovo vaccinated chicks are 
healthier chicks due to a more uniform, and early immunity. Since the vaccination against 
MD proved to be successful, attempts have been made to deliver other vaccines, such as 
infectious bursal disease virus (IBDV) (Haddad et al., 1997), reovirus (Guo et al, 2003), 
DNA (Oshop et al., 2003), infectious bronchitis virus (IBV) (Wakenell et al, 1995), and 
Newcastle disease virus (NDV) (Karaca et al., 1998). One important question addressed 
regarding in ovo vaccination research is the ability of the vaccine to overcome maternal 
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antibodies, mount an immune response, and not interfere with the level of protection 
conferred by MD vaccine. 
1.2. Newcastle disease (ND)
ND is a highly viral contagious, fatal disease of all species of birds. Clinical signs
of ND vary from unapparent to highly virulent forms, depending on the virus strain, 
isolate, and the host species. It’s ethiological agent, Newcastle disease virus (NDV) is 
grouped into three main pathotypes: velogenic, mesogenic, and lentogenic. Velogenic 
strains cause acute, lethal infections of chickens of all ages, and hemorrhagic lesions of 
the digestive tract are frequent. This form of disease is termed viscerotropic velogenic 
Newcastle disease (VVND). Velogenic strains can also cause a second form of disease, 
characterized by respiratory and neurological clinical signs, denoted neurotropic 
velogenic (NVND). A less pathogenic form of NVND affecting young birds is caused by 
mesogenic strains. Mesogenic strains are often used as secondary live vaccines.
Lentogenic strains may cause mild or unapparent respiratory infections, and are routinely 
used as live vaccines (Alexander, 1997).
NDV belongs to the family Paramamyxoviridae, genus Rubulavirus. Members of 
this family are enveloped, nonsegmented, single stranded, negative-sense RNA viruses. 
It’s entire genome consists of 15,186 nucleotides, with six structural genes in the order of 
3’-NP-P-M-F-HN-L-5’, which encodes at least seven proteins (Nakaya et al., 2001; 
Krishnamurthy and Samal, 2000; Phillips et al., 1998; Steward et al., 1993; Peeples, 
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1988). The nucleocapsid protein (NP) binds to the genomic RNA forming the 
nucleocapsid core. The phosphoprotein (P) and the large polymerase protein (L) are 
associated with the nucleocapsid core. Together, they form a tight functional 
ribonucleoprotein (RNP) complex. The matrix protein (M) forms the inner layer of the 
envelope. Hemagglutinin-neuraminidase protein (HN) is a glycoprotein attached to the 
envelope of the virus and it’s responsible for the attachment of the virus to the host cell 
receptor. HN is recognized by the host immune system, and it can elicit a humoral 
immune response. NDV envelope also exhibits another glycoprotein called Fusion (F), 
which mediates fusion of the viral envelope with the host cell membrane. It is considered 
the most immunogenic protein of NDV. 
Mesogenic and lentogenic (La Sota, B1) strains of NDV are widely used as live 
vaccines against ND to protect birds from severe clinical signs. However, it neither 
prevents virus infection in vaccinated flocks nor shedding from vaccinated to 
unvaccinated animals. Live NDV vaccines may cause mild respiratory disease, leading to 
increased susceptibility to secondary bacterial infections. In addition, these viruses are 
attenuated and their capacity to revert pathogenicity, spread to susceptible flocks and 
cause severe disease is always present. Another disadvantage of live vaccines is the need 
for refrigeration, a major problem in developing countries with intensive poultry 
production. Inactivated vaccines use β-propiolactone or formalin to kill the virus, and are 
mixed with aluminum hydroxide or oil-emulsion as an adjuvant. They are expensive to 
produce and to apply, which creates high costs in labor to administer individual 
intramuscular or subcutaneous injections. Such vaccines also cause severe local 
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inflammatory reactions and the site of injection must be removed to improve the 
appearance of the chicken for consumers. 
1.3. Infectious bursal disease (IBD)
IBD, also known as Gumboro disease, is an acute, contagious viral disease of 
poultry. In chickens, three to six weeks of age infectious bursal disease virus (IBDV) 
causes severe immunosuppression and mortality (Lukert and Saif, 1997). IBDV targets 
the lymphoid tissue, specially the B-lymphocytes of the bursa of Fabricius (BF). In 
younger chickens, less than three weeks of age, IBDV causes subclinical disease with 
severe bursal damage, which leads to immunosuppression, increased susceptibility to 
other infections, and vaccination failure (Kibenge et al., 1988).
IBDV belongs to the family Birnaviridae, and genus Avibirnavirus. It is non-
enveloped, and it has two segments of double-stranded RNA. Other members of this 
family include infectious pancreatic necrosis virus (IPNV), tellina virus, sandgoby virus, 
oyster virus, blotched snakehead virus, and the Drosophila X virus. IBDV genome 
consists of a large segment (3.3 Kb) of double stranded RNA, segment A, and a smaller 
segment (2.9 Kb) of double stranded RNA, segment B (Mundt and Muller, 1995; Azad et 
al., 1985). Segment A consists of two overlapping open reading frames (ORF). The larger 
ORF encodes VP2, VP4, and VP3, while the smaller ORF encodes VP5 (Mundt et al., 
1995). Segment B encodes VP1, the RNA dependent-RNA polymerase (RdRp) (Hudson 
et al., 1986; Azad et al., 1985). VP2 is the major structural protein of the virion, and 
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ranges from 41 to 54 KDa. VP5 is a non-structural protein of unclear function, present 
only in infected cells, and it is not required for replication  (Yao et al., 1998).
Vaccination of broiler breeders with live followed by several inactivated vaccines 
is a common practice in the poultry industry. This practice provides passive immunity to 
progeny by the transmission of immunoglobulins (IgY) via yolk (van den Berg et al., 
1991). Live attenuated vaccines produced in tissue culture or chicken embryos can be 
administered via spray, drinking water or eye drop to young chicks. However, it creates a 
concern regarding the optimal time for vaccination of young chicks, since live attenuated 
vaccine virus could interfere with maternal immunity. Besides, an incomplete attenuation 
of IBDV could lead to severe vaccine reaction due to residual pathogenicity. IBDV 
vaccines also present the risk of reversion from attenuated to a more virulent form of 
IBDV in the field, as some other live vaccine does. The level of protection increases 
proportionally to the pathogenicity of the strain used for vaccination. Thus, IBDV strains 
of intermediate virulence present a higher residual pathogenicity that leads to bursal 
damage, and resultant immunosuppression.
1.4. DNA vaccines
DNA vaccines, also called nucleic acid vaccines, genetic vaccines, or naked DNA 
vaccines, are based on recombinant DNA technology, where a DNA sequence encoding 
the protein or proteins of interest is cloned into a eukaryotic expression vector (EEV). 
The constructed plasmid is grown in bacteria (Escherichia coli), purified, and inoculated 
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into the host to be vaccinated. Wolff and co-workers were first to describe that a simple 
inoculation of plasmid DNA could generate protein expression (Wolff et al., 1990). The 
exact mechanism of how DNA vaccines work is not well understood. One hypothesis is 
that after intramuscular injection, the plasmid DNA transfects muscle host cells and 
inside their nuclei starts gene transcription. The resulting mRNA goes to the cytoplasm 
and initiates protein translation. The resultant protein of interest is processed and 
presented to the immune system. DNA vaccines are able to induce cytotoxic T 
lymphocyte (CTL) via the major histocompatibility complex (MHC) class I. Humoral 
response is generated by free antigens, and by antigen presenting cells (APCs), which 
activate T-helper cells via the MHC-II pathway (Robinson, 1997). The first report of 
DNA vaccinations was published in 1992 using mice as a model and gene-gun as the 
delivery technique (Tang et al., 1992).
Most of the knowledge regarding DNA vaccines was generated using mice as a 
model in order to study human diseases. In poultry, several DNA vaccines were tested 
against many pathogens, such as infectious laryngotracheitis (Keeler, 2000; Cheng et al., 
2000), avian influenza (Kodihalli et al., 1997; Robinson et al., 1993; Fynan et al. 1993), 
coccidia (Song et al., 2001), IBDV (Oshop et al., 2003; Wu et al, 2000; Fodor et al., 
1999), infectious bronchitis virus (Kapczynski et al., 2003; Seo et al., 1997), and NDV 
(Oshop et al., 2003; Sakaguchi et al, 1996). The use of DNA technology in poultry to 
generate specific antibodies for diagnostic purposes was also described successfully using 
the H5 gene from avian influenza (Lee et al., 2003).
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A better delivery system for DNA vaccination has to be developed for its use in 
poultry, where a large number of birds must be vaccinated without the need to inject 
individual birds. One approach for large-scale delivery is in ovo. The use of DNA 
vaccines in ovo has not been studied in great detail and many aspects that could 
compromise vaccine efficacy were not addressed.    
1.5. Rationale and significance 
Commercial poultry comprises the largest segment of food animal production 
globally. Most of the live vaccines have been developed by manipulation of pathogenic 
microorganisms, such as virus attenuation by in vitro passage or by chemical treatment. 
These procedures cause changes in their genomes. Although the current vaccines 
available to control ND and IBD have greatly contributed to the health of commercial 
poultry, these vaccines are not risk free. It is well documented that IBDV vaccines do 
cause minor immunosuppression. Live NDV vaccines may cause mild respiratory 
disease, leading to increased susceptibility to secondary bacterial infections.
IBDV and NDV are viruses of major economic importance to the poultry industry. 
There are several reports of isolation of very virulent strains in Asia, Europe, and South 
America as well as antigenic variants of IBDV from vaccinated flocks, in the US. These 
variant strains of IBDV are able to break maternal immunity and induce disease (Snyder 
et al., 1992; van den Berg et al., 1991; Chettle et al., 1989). 
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There is a clear need for a more efficient vaccine in order to control, prevent or 
even eradicate IBD. It has to be a vaccine capable of protecting young flocks from 
immunosuppressive as well as classic forms of the disease. 
1.6. Research objectives 
We propose to develop and evaluate a more effective way to protect poultry flocks 
against IBDV. In our first objective, we plan to use a well-established practice of in ovo
vaccination and optimize a delivery system using a DNA vaccine expressing the 
hamagglutinin-neuraminidase (HN) gene from NDV. In second objective, a DNA vaccine 
against IBDV will be constructed and delivered following the criteria established in the 
first objective. Our DNA-based and live attenuated vaccine will be constructed to express 
epitopes from standard D78 vaccine strain, and the variant GLS strain. We intend to test 
the IBDV vaccines (DNA and recombinant) in specific-pathogen-free (SPF) and 
commercial 18-day-old embryos to examine the possibility of maternal antibodies 
interference. 
Initially, we planned to work on DNA vaccines for NDV. However, challenge 
studies to assess protective immunity would require a biological level three (BL3) 
facility, unavailable at this moment. So, we decided to switch to a plasmid expressing 
structural proteins (VP2-VP4-VP3) of IBDV that requires a BL2 facility. All preliminary 
results obtained from DNA-NDV studies will be used in the following experiments for 
IBDV. The air cell and the amniotic routes will be compared for in ovo DNA vaccination. 
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In a separate experiment, we will also compare two formulations for DNA vaccine 
delivery, a transfection reagent (PEI-ExGen®) and dimethylsulfoxide (DMSO) 
associated with incomplete Freund’s adjuvant (IFA). We will use the information 
regarding route and formulation gathered previously to compare five different dosages of 
plasmid DNA. In a final in vivo experiment, we will access the humoral immune response 
after hatch of in ovo DNA vaccinated chickens.
The plasmid DNA encoding IBDV proteins will be used to address the issue 
regarding maternal antibody, and vaccine safety and efficacy. Eighteen-day-old, SPF 
embryonated eggs will be compared to broilers to assess the ability of the virus to break 
through the maternal antibody barrier and mount a protective immune response against 
IBDV challenge. 
We also propose to verify the possible use of a recombinant live attenuated vaccine 
by in ovo delivery into SPF eggs (lacking maternal antibody), and also in a commercial 
fertile broiler eggs facing standardized challenge studies against IBDV.  This vaccine was 
developed earlier in our laboratory. Vaccine efficacy will be determined following the 
standard OIE requirements. All animal studies will be performed accordingly to protocol 
approved earlier by the Institutional Animal Care and Use Committee, University of 




2.1. In ovo technologies
The American poultry industry is one of the most prominent in the world. 
Commercial hatcheries in the 19-state weekly program set 206 million eggs per week in 
2003, a 3 percent increase compared to last year. Average hatchability for chicks hatched 
during this period was approximately 83 percent (WATT poultry publication, Monday 
December 29, 2003). In order to keep up with this fast pace, this industry is developing 
new technologies in all sectors of production. In the hatchery, in ovo technologies were 
created to sex, candle, vaccinate, and transfer fertile eggs to increase productivity. 
The embryo development takes place outside the hen’s body, and it can be easily 
manipulated to improve poultry production. Considering that a broiler chick reaches 
marketable weight in 32 to 48 days, the embryonic period composes 30-40% of a 
broiler’s total lifespan, and represents a crucial phase in the avian production life cycle. 
Minimal changes regarding temperature, setting position, humidity, and contamination 
levels can have tremendous consequences in broiler performance.
In ovo technology was initially developed for the application of Marek’s vaccine 
in 18-day-old embryos (Sharma and Burmester, 1982). Today, this technology is also 
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used for antibiotic therapy, delivery of other vaccines besides Marek’s, egg-candling to 
determine viable fertile eggs, and transfer from incubators to hatchers. Also, in ovo
technologies are being used to provide samples for diagnosis to help disease surveillance 
and epidemiological studies. The next revolutionary use of this technology is under way 
to select embryos by sex and even more ambitiously, to change the sex of the embryo by 
the introduction of avian embryonic stem cells (Ricks et al., 2003). In certain sectors of 
production, such as egg production, a female sex is more desirable. In broilers, males in 
general have better feed conversion than females. Additionally, broilers reach marketable 
weight much faster than females. Under these circumstances, males are highly desirable. 
This new technology is still in its infancy but it won’t be too long before it’s available for 
commercial use. 
2.2. In ovo vaccination
Embryo vaccination was developed in order to provide adequate time for chicks 
to respond to MD vaccination before exposure to field virus. MD is a highly contagious 
malignant T-lymphomatosis of chickens caused by virulent MDV. MD was controlled for 
years by vaccination. It was the first cancer-causing virus that could be prevented through 
immunization. Vaccine viruses include apathogenic MDV1, naturally apathogenic MDV 
serotype 2 (MDV2), and HVT serotype 3 (MDV3). However, during the 1980s, MD 
control became less successful when more virulence strains of the virus appeared in the 
field. In 1992, embryo vaccination against MD was introduced commercially to 
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hatcheries in the USA in order to confer early protection to young chicks exposed to field 
challenge (Sharma et al. 1982).
Commercial in ovo vaccination of embryos between days 18 and 19 of incubation 
against MD with HVT started in 1992 (Sharma, 1987). At eighteen days of incubation, 
the eggs are removed from the incubators, vaccinated against MD, and transferred to the 
hatchers. Not all vaccines currently licensed for MD have been approved for use in ovo. 
However, some of the currently available HVT, SB-1, and serotype 1 vaccines (CVI-988) 
have been approved for in ovo administration (Wakenell, et al., 2002). 
HVT vaccines after in ovo inoculation resulted in high titers of the virus in non-
lymphoid, and non-macrophage cells in the lungs of the embryos indicating the 
importance of this organ to induce proper immunity (Sharma, 1987). 
Many factors may influence the efficacy of vaccines delivered in ovo. The 
embryo position is one of them. The location of the embryo or surrounding fluids is 
dependent on the percentage of water loss from the embryonated eggs to the environment 
through incubation, the embryo’s age at inoculation, and the size of the eggs (Wakenell et 
al., 2002). The egg size is influenced by the age of the hen. Older breeders lay bigger 
eggs.  Needles used for automated in ovo injection present a standard length. Thus, eggs 
presenting a larger size may not allow the vaccine to be inoculated into the desired 
amniotic cavity. Another important factor is the status of the maternal antibodies 
transferred from the yolk to the embryo after 18-19 days of incubation. Many vaccines 
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are unable to overcome the maternal antibodies and establish an immune response. 
Maternal antibodies induced by heavy immunization of breeders could neutralize the in 
ovo administered vaccine. On the other hand, if the vaccination of young chicks is 
delayed until the maternal immunity wanes, these birds may have an interval where they 
would be more vulnerable to viral infection since the active protection by immunization 
may not be available yet.
At eighteen days of embryonation, when most in ovo vaccination occurs, fertile 
chicken eggs consist of four compartments: 1) the air cell, 2) the allantoic sac, a fluid-
filled compartment positioned along the shell and below the air cell membrane, 3) the 
amniotic sac, which surrounds the amniotic fluid, yolk sac, and embryo and 4) the yolk 
sac, which lies within the amniotic sac. Beginning on day 16-17 of incubation and 
continuing on day 18, a normal embryo increases in size and pushes the allantoic fluid to 
the sides and to the small end of the egg. At the same time, the total volume of allantoic 
fluid is rapidly reduced because of water resorption by the embryo and moisture loss 
through the eggshell. The yolk sac is being absorbed by the embryo to inside its 
abdominal cavity (Wakenell et al., 2002).   
Commercially, the amniotic cavity is the target for in ovo injection. Wakenell and 
co-workers evaluated one-day-old chicks vaccinated subcutaneously, and four in ovo
routes (amniotic, allantoic, air cell, and embryonic) using a HVT/SB1 MDV vaccine. 
Embryos vaccinated via air cell were not protected against MD-RB1B challenge. 
Challenge protection results of birds vaccinated at hatch were similar to results verified in 
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embryos vaccinated by the amniotic and embryonic routes when challenged at 5 days 
post-hatch (Wakenell et al., 2002).
Zhang and Sharma, addressed the concerns regarding inducible immunological 
tolerance by in ovo vaccine administration. HVT was injected in ovo in different stages of 
embryo development. The inability to show HVT antibody response by serologic assays 
was the criteria used to verify immunotolerance in viremic birds. Embryos exposed to 
HVT at fourteen days of incubation or earlier presented significant tolerance (Zhang and 
Sharma, 2003). 
Many attempts to use in ovo vaccination against an important poultry pathogen, 
IBDV have been made. Sharma evaluated a low virulence IBDV vaccine (TC-IBDV and 
BVM-IBDV) by inoculating 18-day-old embryos and challenging them at 3 weeks of age 
(Sharma, 1985). Protection of the in ovo vaccinated group was similar to the group 
vaccinated at one-day of hatch and hatchability was not affected by the vaccine. 
However, in ovo vaccinated chicks exhibited bursal damage, as verified by 
histopathology, in a higher degree than birds vaccinated at hatch. Also, the dual 
vaccination against IBDV and MD was evaluated. Dually vaccinated group showed 
similar protection against both diseases when compared to chickens vaccinated with 
single vaccines (Sharma, 1985). In a different experiment addressing the use of in ovo
vaccine against IBDV, embryos vaccinated with different dosages of a BVM strain of 
IBDV showed virus replication in several tissues at one day up to 7 days post-
vaccination. Lung, thymus, proventriculus, liver, kidney, and spleen were the main sites 
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for virus replication. Tissue distribution after in ovo vaccination showed similar results 
when compared with birds vaccinated at hatch. In addition, vaccination in ovo generated 
a protective immunity against IBDV challenge at 4, 6, 8 and 10 weeks post-hatch. The 
lowest dosage tested (6.2 median embryo lethal dose) was also able to protect vaccinated 
birds against IM-IBDV challenge strain (Sharma, 1986).
Live intermediate IBDV vaccines (containing classic strains of the virus) from 
three different vaccine companies were administered in ovo, and evaluated for safety and 
efficacy. In ovo vaccination with a half dose of vaccine in commercial broilers (with 
maternal immunity) conferred protection against standard and variant strains of IBDV 
(87-94%, and 60-74% respectively). Minor bursal damage was observed at one-day post-
hatch but not at 3 weeks. Hatchability and post-hatch survival was not affected. The 
authors indicated the need for a higher protection against variant strains, and proposed to 
evaluate a new vaccine that includes antigenic variant strains for in ovo use (Giambrone 
et al., 2001). 
More recently, a new generation of live attenuated vaccines was created against 
reovirus and IBDV, where there is a formation of an immune complex of IBDV or 
reovirus with its specific antibodies. Against IBDV, there are two commercial vaccines, 
named CEVA Transmune IBDV vaccine, and IBDV-Icx, respectively, produced by 
Embrex Inc., Research Triangle Park, NC, and CEVA-Phylaxia Ltd., Budapest. Ivan et 
al. evaluated the transient bursal damage caused by CEVA vaccine. CEVA Transmune 
IBDV vaccine contains an IBDV strain (identified as 2512), containing 10 2.0 EID50% 
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per recommended dose. In ovo vaccinated birds demonstrated depletion of bursal 
follicles, detected by immunohistochemistry in SPF and broiler birds. Bursal damage in 
broilers was detected later in age, and it was less severe than in SPF birds and of less 
duration (Ivan et al., 2001). The second experiment described below also evaluated the 
immune response of birds vaccinated with an immune complex against IBDV. IBDV-Icx 
and IBDV-2512 attenuated strain were injected in ovo. Neither vaccine mounted an 
antibody response by 21 days post-vaccination. Birds vaccinated with IBDV-Icx were 
challenged at 21 and 35 days after vaccination and showed respectively 83%, and 77% of 
protection against standard challenge strain of IBDV. The IBDV-2512 vaccinated birds 
presented bursal atrophy; protection was not evaluated. The lack of humoral responses 
indicated the presence of cellular immunity since degrees of protection was still observed 
(Corley et al., 2002). The cell immunity role played in protection was evaluated in a 
different experiment by Corley et al., 2002. SPF embryos were vaccinated at 18 days of 
incubation with IBDV-Icx and IBDV-2512. T cell mitogenic responses, CD4+, CD8+ T 
cell profile, and B cell percentages were examined. The T cell response assay in birds 
vaccinated with IBDV-2512 induced greater T cell suppression than IBDV-Icx. This 
suppression was not related to the proportion of T cell since the T cell profile was similar 
to both vaccines. The detection of B cells by flow cytometry revealed a decreased 
percentage for both vaccines when compared to unvaccinated group (Corley et al., 2002). 
Guo, and co-workers described immune complex vaccines against reovirus. Reovirus 
vaccine strain was compared with vaccines containing the same virus vaccine strain 
combined with different dilutions of the antibody for the immune complex. All vaccines 
were administered in ovo at 18 days of incubation. Birds vaccinated with immune 
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complex had delayed antibody responses and virus recovery when compared to birds that 
received the virus alone. Post-hatch mortality was 13.3% lower in the immune complex 
vaccinated group (Guo et al., 2003).
Attempts to vaccinate chicken embryos against IBV were also made. IBV is an 
economically important, highly contagious disease caused by a coronavirus. Wakenell 
and collaborators compared chickens vaccinated in ovo and at hatch using the virulent 
Holland strain (vIBV), and commercially available Massachusetts type (106 EID50%), 
which was attenuated after 40 passages in tissue culture (p-IBV). High antibody 
responses were observed between birds vaccinated in ovo with either vaccine. The p-IBV 
caused more lesions in the trachea and lungs when administered in ovo, and similar 
lesions were also observed in one-day-old birds vaccinated with v-IBV. Trachea and lung 
lesions were almost nonexistent at 17 days post-hatch. No kidney lesions were observed 
in any vaccinated group (Wakenell et al., 1995). Another study evaluating the use of live 
attenuated vaccines in ovo against IBV was reported by Kapczynski and co-workers. 
Embryos were vaccinated after 18-days of incubation, in the chorioallantoic sac, using 
the Arkansas serotype of IBV strain. Tissue distribution was determined by probing 
bursa, lung, spleen, heart, and thymus with a digoxigenin-labeled antisense S1 riboprobe 
to detect viral mRNA. Tissues were collected 24, 48, 72 and 120 h post-inoculation. 
Samples from the lungs were positive for IBV 24, 48 and 72 h after inoculation, and 48 h 
post-inoculation in the BF. No viral mRNA was detected in heart, thymus, or spleen at 
any time point. These results suggest that an initial infection by IBV in the lungs of 
inoculated embryos spread further to the BF (Kapczynski et al., 2002).
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In ovo vaccination against NDV using fowlpox virus (FPV) as a vector was also 
examined (Karaca et al, 1998). Interestingly, this construct not only expresses the HN and 
F genes of NDV but also the gene encoding interferon type I (IFN). One-day-old SPF 
chicks and 17-day-old embryonated eggs were inoculated with FPV, FPV-NDV, FPV-
IFN, and FPV-NDV-IFN. Two weeks after hatch, the birds were challenged with NDV-
GB Texas (standard NDV challenge strain). No significant differences were reported 
regarding body weight among all groups. Animals from FPV-NDV-IFN and FPV-NDV 
were fully protected against challenge. Challenge against FPV was also performed and all 
groups (in ovo/one-day old) were protected (90%). All groups exhibited a humoral 
response to NDV by ELISA and virus neutralization assays (VN). However, the group 
vaccinated with FPV-NDV-IFN showed significantly lower titers. The authors attributed 
lower humoral responses to a down regulation played by IFN type I (Karaca et al, 1998). 
A similar study was performed in turkeys by the in ovo route, using FPV as a vector for 
NDV and interferon type I and II. Hatchability, survival, performance and weight again 
were not significantly different among vaccinated groups. Higher antibody responses and 
protection against NDV challenge was detected in turkeys that received FPV-NDV-IFN-
II vaccine. Interferon-γ (IFN type II) is a potent macrophage activator, and 
immunomodulator. The authors speculated its role as a vaccine adjuvant to justify the 
better results presented by FPV-NDV-IFN-II (Rautenschlein et al., 2000).
The immunity of an avian pneumovirus vaccine administered in ovo was also 
evaluated in turkeys. Turkey embryos after 24 days of incubation without maternal 
antibodies, received a live attenuated vaccine with a dose 10 times higher than the 
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manufacturer’s recommendation. Hatchability was not affected by the vaccination and 
100% protection was observed at both 3 and 5 weeks post-hatch (Worthington et al.,
2003).
2.2.2. In ovo vaccination against multiple viral agents
Vaccination programs vary among different companies. One-day-old chicks may 
receive many live vaccines in addition to Marek’s. Live attenuated vaccines against IB, 
ND, and in some cases IBD may be administered in the hatchery via spray or at the 
poultry farm via drinking water, and spray.  Thus, many researchers, intending to take 
advantage of the in ovo technology, have been studying the possibility of administrating 
multivalent vaccines against several poultry pathogens. This way, vaccination at one-day 
of age could be avoided, resulting in less labor, handling stress and more uniform 
performance. The possible drawback of this methodology is the interference among 
vaccine viruses competing to infect, replicate and stimulate the relatively immature host 
immune system. This concern is addressed in the following reports. 
The use of in ovo vaccination against NDV presents another challenge, since all 
conventional vaccine strains of the virus that are nonpathogenic for hatched birds are 
lethal for the developing embryos (Ahmad et al., 1992). Therefore, a group of researchers 
used a recombinant FPV vaccine expressing the HN and F gene of NDV. SPF, 18-day-
old embryos were vaccinated with a recombinant cell-associated HVT expressing the 
NDV gene, and glycoproteins A and B of MDV. The same vaccination program was 
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applied in one-day old chicks. Control groups consisted of unvaccinated birds, HVT 
alone, and a NDV-B1 treated with ethylmethane sulfonate. Chicks vaccinated at one-day 
of age and in ovo exhibited similar results. Hatchability and survival were not affected. 
Birds were considered protected after challenges against NDV (NDV-GB Texas) and 
against MD (RB1B) at 4 weeks post-hatch. However, the challenge NDV was isolated 
from the trachea of vaccinated birds, indicating partial protection (Reddy et al., 1996).
Stone and co-workers assessed protection against avian influenza (AI) and NDV 
using inactivated vaccines in ovo. The inactivated vaccine (inactivated by beta-
propiolactone treatment) consisted of the Ulster strain of NDV, and H5N9 type of AI 
propagated in 9-day-old embryos. The inactivated virus mixture was emulsified in an oil-
based solution (Drakeol) and inoculated into embryos with three different virus 
concentrations per egg (1X, 5X, 10X). Seroconversion was observed 2 weeks post-hatch 
by hemagglutination inhibition assays (HI). Complete protection was observed against 
NDV and influenza challenge at 53, and 34 days post-hatch, respectively (Stone et al., 
1997).
SPF embryos that were vaccinated with a multivalent vaccine against MD, IBDV, 
FPV, and NDV, were fully protected against challenge. The vaccine mixture consisted of 
a commercially available recombinant FPV vaccine expressing NDV genes; serotypes 1, 
2 and 3 of MD (CVI988, 301/B1, HVT), and of an IBDV strain (2512). The vaccine 
mixture induced antibody immune response and did not affect survival. Unfortunately, 
hatchability was decreased 23-26% when rFVP-NDV was present in the mixture (Gagic 
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et al., 1999). This same mixture was used in commercial embryonated eggs containing 
maternal antibodies. Protection against IBDV, NDV, and FPV was 100%, 81%, 86%, 
respectively. Birds vaccinated in ovo against MD with HVT alone, at one-day-old against 
IBV and NDV, and boosted 2 weeks later with IBV and NDV, gave 100%, 19% and 0% 
protection (Sharma, 2002).
Guo and co-workers determined the association of Marek’s vaccine, and immune 
complex vaccine against reovirus. SPF embryos were vaccinated in ovo with an immune 
complex formed by reovirus vaccine (Synvac, 103.5 TCID50%), and serum from 
hyperimmunized chickens, diluted to 1:8. Commercial embryos with maternal antibodies 
were vaccinated with a 1:16 serum dilution in the immune complex. The vaccine against 
MD was a bivalent HVT/SB1 administered alone or associated with reovirus immune 
complexes. One half of all groups were challenged against MD at 5 days post-hatch, and 
the other half against reovirus 7 days post-hatch. Neither vaccines affected hatchability or 
survival. No significant differences in protection were observed in reovirus vaccinated 
birds with or without MD vaccine. On the other hand, commercial broilers exhibited 
lower protection levels, indicating that maternal antibodies may interfere with vaccine 
efficacy. Birds were also protected against MD challenges. However, a lower, 
statistically insignificant difference was observed in birds challenged against MD when 
the vaccine was administered in association with reovirus (Guo et al., 2003).
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2.3. Newcastle disease 
ND is a severe respiratory, neurological, or enteric disease accompanied by high 
mortality in chickens, which causes significant economic losses to the poultry industry. It 
can infect all species of birds. The disease exhibits different degrees of severity, 
depending on the pathotype. The virus is categorized in three main pathotypes: velogenic, 
mesogenic, and lentogenic. Velogenic strains can produce acute infections with high 
mortality. Mesogenic strains exhibit intermediate virulence and more moderate clinical 
signs. Lentogenic strains may cause mild disease in birds and are often used as live 
vaccines worldwide (Alexander, 1997).
2.3.1. History of ND
Virus isolation techniques were not available when the first ND outbreak 
occurred. Thus, it is almost impossible to state when the first ND outbreak happened. 
However, the first official ND outbreaks caused by a Paramyxovirus type 1 (PMV-1) 
were reported in Java, Indonesia in 1926, and in Newcastle-upon-Tyne, England. There 
are earlier reports of this disease from Korea and Central Europe. The disease was named 
“Newcastle disease” by Doyle in 1926. 
PMV type 2 was isolated in 1956 by Bankowski from a chicken exhibiting 
respiratory clinical signs of ND. Epidemiological studies of PMV-2 reported a wider 
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distribution in turkeys than in chickens. In exotic birds, PMV-2 was primarily identified 
in passerines and psittacines. 
PMV-3 was originally isolated from turkeys in Ontario in 1967, Wisconsin in 
1968, and several European countries. Later, PMV-3 was also serologically identified in 
many other states in the US.
2.3.2. Epidemiology
The severity of NDV varies greatly depending on the host and strains. Also dose, 
route of administration, host’s age, and environmental conditions play major roles in the 
severity of clinical signs.  NDV has been isolated in more than 236 species from 27 of the 
50 orders of birds. In commercial poultry, chickens are the most susceptible. In contrast, 
ducks and geese may be infected and show few or no clinical signs of the disease, even 
when infected with strains lethal for chickens. The disease is more severe in young 
chickens. Young flocks infected by virulent strains may cause high mortality, without 
symptoms. Oral, nasal, and ocular routes are considered natural routes of infection and 
cause predominantly respiratory signs. Intramuscular, intracerebral, and intravenous 
infection cause mainly neurological signs (Alexander, 1997). 
NDV can be transmitted by aerosol and also by ingestion. Large amounts of virus 
are excreted in the feces and it is a main source of infection. Oral transmission can also 
occur by contaminated feed (Alexander, 2001). Transmission via parent to progeny is still 
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unclear. Experimental studies to address vertical transmission were inconclusive because 
of mortality during incubation of infected embryos (Lancaster et al., 1975). Another 
important source of infection is by humans and equipment. Vaccination crews moving 
from one flock to another may have their conjunctival sacs infected with NDV or may 
spread the virus by contaminated clothing, and shoes (Alexander, 1997).
The incubation period of ND varies between 2 to 15 days after natural exposure. 
NDV is sensitive to heat, irradiation, oxidation processes, pH, and chemical compounds 
and these processes dramatically reduce its infectivity.
2.3.3. Diagnosis of ND
ND has no pathognomonic lesions or hallmark clinical signs. Intestinal contents 
or cloacal swabs, feces, and trachea swabs or trachea tissues are the preferred material for 
virus isolation in 9-10 days embryonated chicken SPF eggs. When neurological clinical 
signs are present, brain should also be included for virus isolation. Vaccination with a 
live attenuated strain is a common practice and as a consequence it is impossible to 
distinguish vaccinated from infected birds. Thus, serology has limited diagnostic value. 
Serology techniques, such as HI, VN in chicken embryos, single radial immunodiffusion, 
single radial hemolysis, agar gel precipitin, plaque neutralization, and ELISA have 
significant importance in post-vaccinal monitoring or for diagnosis in non-vaccinated 
flocks (OIE, 2000).                                                                                            
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To measure the true virulence of the isolated virus, laboratory assessment of the 
pathogenicity of the virus is necessary. Three in vivo tests are used: mean death time in 
eggs (MDT), intracerebral pathogenicity index in one-day-old chicks (ICPI), and 
intravenous pathogenicity index in 6-week- old chickens (IVPI).
2.3.4. Prevention and control
International control policies vary greatly depending on the status of the disease in 
each specific country. Countries free of the disease do not vaccinate and do not allow any 
form of NDV to be introduced. Others allow the presence of only live attenuated vaccines 
made of lentogenic strains. Some countries have very virulent strains of NDV and the 
control is through vaccination (Alexander, 1997).
In the US, control policy is to prevent the introduction of virus and prevention of 
spread by strict surveillance, and quarantine. Prevention is reached by biosecurity 
practices and vaccination in areas of high risk. ND vaccination reduces the appearance of 
serious clinical signs. However, it does not block infection, replication, and viral spread.  
Live vaccines from lentogenic strains, such as Hitchner B1 and La Sota are 
widely administered to broilers by eye-drop, spray or drinking water. Even though the 
immune response increases as the pathogenicity of the live vaccine increases, mesogenic 
strains of NDV are used only in secondary vaccination due to the risk of vaccinal 
reaction. Inactivated vaccines are produced from allantoic fluid, treated with beta-
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propiolactone or formalin to kill the virus, and then mixed with an adjuvant. These 
vaccines are used in broiler breeders and layers. In broiler breeders, inactivated vaccines 
are used not only to prevent disease, but also to confer high level of antibodies to the 
progeny. Maternal antibodies are protective against NDV. Thus, it must be taken into 
account when timing primary vaccination of broilers (Alexander, 1997).
2.4. Newcastle disease virus 
NDV is a member of the genus Rubulavirus, family Paramyxoviridae, and 
subfamily Paramyxovirinae. Many other important viruses belong to this family, such as 
simian virus 5 (SV5), mumps virus, and human parainflueza virus type 2, 4A, and 4B. 
NDV is included in the Rubulavirus genus because of their non-conserved intergenic 
sequences and lack of a C-protein open reading frame (Lamb and Kolakofsky, 2001). 
This classification is controversial because the organization of the NDV P gene and its 
mRNA editing profile resembles those of the genera Morbillivirus and Respirovirus, 
characteristics not present in the Rubulavirus genus (De Leeuw and Peeters, 1999). 
2.4.1. Virion structure
Negative contrast electron microscopy of members of the Paramyxovirus genus 
shows very pleomorphic virus particle, generally round, ranging in size from 100-500 nm 
in diameter. However, filamentous forms of about 100 nm with variable length can also 
be seen. NDV virions are composed of a bilayer envelope derived from the host cell and 
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an internal ribonucleoprotein (RNP) core.  The surface of the virus particle is covered 
with projections about 8 nm in length. The larger projection is formed by HN protein, and 
it is responsible for hemagglutinin and neuraminidase activities. HN is a 75 KDa protein 
responsible for attachment of the virus to host cell receptor. The smaller projection, 
fusion (F) is a 66 KDa protein and it mediates fusion of viral envelope with host cell 
membrane. The HN and F are the major proteins recognized by the host immune system. 
Interactions of these two glycoproteins facilitate the virus entry and release, which 
subsequently play a very important role in viral virulence (Stone-Hulslander and 
Morrison, 1997).
Matrix protein (M) is located inside the envelope between the inner membrane 
and the nucleocapsid core. M is implicated in the final assembly of virus particles 
(Peeples, 1991). The core has helical capsid symmetry and contains the single negative 
stranded genomic RNA (Nakaya et al., 2001; Krishnamurthy and Samal, 2000; De Leeuw 
and Peeters, 1999; Phillips et al., 1998). The genomic RNA contains 15,186 nucleotides 
and is encapsidated by nucleocapsid protein (NP). The NP, P, and L proteins, plus the 
genomic RNA form a complex, called RNP complex. 
2.4.2. Genome structure and organization
The NDV genome is a negative stranded RNA, encoding six genes:  3’-NP-P-M-
F-HN-L-5’. These genes are monocistronic, coding for a protein with the equivalent 
name. The only exception is the P gene, which encodes two additional proteins, V and W, 
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by RNA editing (Steward et al., 1993). In between these genes there are two consistent 
regions, 3’ extracistronic region containing 55 nucleotides and known as the leader 
region, and a 5’ extracistronic region of 114 nucleotides, known as the trailer 
(Krishnamurthy and Samal, 2000). These two regions are involved in the control of virus 
transcription and replication (Lamb and Kolakofsky, 2001). In the beginning and end of 
each gene, there are conserved transcriptional control sequences known as gene-start and 
gene-end. The NDV genome also consists of intergenic regions between each gene. 
These regions consist of 1 to 47 nucleotides (Krishnamurthy and Samal, 2000).
2.4.3. Viral proteins
The viral nucleocapsid formed by NP, P and L proteins, and the genomic RNA, is 
considered the minimum infectious unit of NDV. All the enzymatic activities required for 
transcription, replication and translation are associated with the nucleocapsids.
The 53 KDa NP surrounds the viral RNA. It plays a major role in virus 
replication, including encapsidation of genomic RNA to form RNase-resistant 
nucleocapsid, association with P-L polymerase during transcription and replication, and, 
most likely, interaction with M protein during virus assembly. Unassembled NP 
concentration inside the cell controls the relative rate of viral transcription and replication 
(Errington and Emmerson, 1997).
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P protein of NDV is rich in serine and threonine residues, which are potential sites 
for phosphorylation (Steward et al., 1993; McGinnes et al., 1988). P is involved in the 
formation of the viral polymerase complex when associated with L protein. It is also 
involved in the formation of P-NP complex and acts as a transcription and replication 
factor. In other paramyxoviruses, phosphorylated P protein is a regulator factor in RNA 
synthesis (Lamb and Kolakofsky, 2001). P gene is able to produce two additional 
proteins (V and W), by transcriptional modification of the mRNA by insertion of one or 
two non-template G residues respectively into the newly synthesized mRNAs (Steward et 
al., 1993). 
The L protein is the largest protein of NDV. However, it is the least abundant one. 
L is also the major component of the RNA-dependent RNA polymerase in negative-
stranded RNA viruses. L is responsible for mRNA capping and it is also involved in the 
formation of P-NP complexes.
M protein is located in between the inner layer of the envelope and the 
nucleocapsid core. Function of the M protein is to coordinate virus assembly (Peeples, 
1991). It interacts not only with the lipid layer of the envelope and the nucleocapsid, but 
also with sites of HN and F on the surface of the virion.
HN is the largest glycoprotein of NDV. It is a type-II membrane protein. The host 
immune system recognizes this glycoprotein and elicits an antibody response.  It has 
hemagglutinin (HA) and neuraminidase (NA) activities. The main function of HN is to 
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mediate virus attachment to the host cell receptors. The neuraminidase enzymatic activity 
prevents virus aggregation on the plasma membrane during budding. HN is also involved 
in cell fusion, indicating that the coexpression of HN and F is required for cell-cell fusion 
(Hemingway et al., 1995). 
F glycoprotein is involved in cell-cell fusion and virus-cell fusion (Morrison et al., 
1985). This fusion is pH-independent. The fusion protein is a type-I membrane protein 
and is synthesized as an inactive form (F0). Trypsinlike protease cleaves F0, which 
results in two disulfide-linked subunits, F1 and F2. Only after this proteolytic cleavage, 
fusion can take place between the envelope of the virus and host cell membrane (Gotho et 
al., 1992; Morrison et al., 1985; Hsu et al., 1983). The cleavage of F0 is the major 
virulence aspect of NDV (Peeters et al., 2000).
2.4.4. NDV replication, transcription, translation, and assembly 
NDV replication follows the same pattern of other non-segmented negative-strand 
RNA viruses. All stages of NDV replication take place entirely within the cytoplasm. 
Replication is initiated when HN protein attaches to specific cell surface receptors 
containing sialic acid (Huang et al, 1980). Fusion protein mediates the fusion of the viral 
and the host cell membrane. Fusion occurs at neutral pH. The fusion protein precursor 
(F0) is cleaved by proteases to the active form, a disulfide bond-linked heterodimer 
composed of F1 and F2 (Morrison et al., 1985; Hsu et al, 1983; Kohama et al., 1981). 
This cleavage results in an F1 polypeptide with a highly conserved amino acid sequence 
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at the N-terminus, termed “the fusion sequence”. This sequence is believed to mediate 
fusion between membranes (Hsu et al., 1983; Richardson and Choppin, 1983). Thus, 
proteolytic cleavage of the F0 protein is known to be a major determinant of virulence 
and essential for initiation of infection. In virulent strains of NDV, the F0 protein can be 
cleaved post-translationally by host protease in a large variety of cell types and tissues, 
allowing the virus to cause a more severe clinical disease with systemic consequences. In 
strains of low pathogenicity, cleavage of F0 is accomplished by a more specific cell type, 
such as endodermal cells of chick embryo. For this reason, these viruses can replicate 
only in certain type of host cells, which induces a more local infection (Nagai et al., 
1976). HN is also involved in the fusion of membranes by triggering a conformational 
change in the F protein after attachment to cell receptors (Hemingway et al., 1995; Lamb, 
1993; Morrison et al., 1991). Following fusion, the nucleocapsid complex enters the cell.
After entering the cell, the nucleocapsid complex is transcribed by the viral RNA-
dependent RNA polymerase (RdRp), which results in 5’ capped and 3’ polyadenylated 
mRNAs (primary transcription). Viral proteins are translated from the primary 
transcription mRNAs. Newly synthesized viral proteins help in the replication of genomic 
RNA, and this serves as template for further transcription (Peeples, 1988).
RdRp starts to transcribe the genome at the 3’ end, more precisely in the short 
leader sequence. After that, the viral polymerase transcribes all the genes in a sequential 
order by terminating and reinitiating at each gene junction. The junctions consist of gene-
end sequence, a short variable non-transcribed intergenic region, and a gene-start 
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sequence. There is a loss of transcription of downstream genes due to a failure of RdRp 
to reinitiate transcription. As a result, there is a polar attenuation of gene transcription. 
When sufficient amounts of unassembled NP protein are present after translation, genome 
replication starts with the synthesis of a full-length complementary copy, called 
antigenome (+). RdRp uses the antigenome as a template for the synthesis of new viral 
genomes. It has been shown that NDV replication follows the ‘rule of six’ (Peeters et al., 
2000). Related to this, is the fact that each NP monomer associates with six nucleotides 
of the genomic RNA (Calain and Roux, 1993). Thus, when the length of the viral genome 
is a multiple of six, replication takes place more efficiently. NP mediates encapsidation of 
the genome and antigenome. The leader and trailer regions of the genome control 
initiation of encapsidation.
In the first step of viral assembly, there is a formation of a helical RNP structure 
mediated by the encapsidation of the genomic RNA with unassembled NP protein. 
Subsequently, there is an association of RNP structure to P-L protein complex forming 
the nucleocapsid. The envelope is assembled at the cell surface. All the steps involved 
during viral assembly are still unknown. The viral M protein is thought to be the major 
driving force that brings the assembled RNP core to the plasma membrane (Peeples, 
1991). The virus is released by budding through areas embedded by viral envelope 
glycoproteins in the host plasma membrane.
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2.5. Infectious bursal disease (IBD)
IBD is an acute, contagious viral infection of young chickens. The virus affects 
the lymphoid tissue, mainly the B cells of BF. Thus, the most prominent lesion is necrosis 
of the BF, sometimes accompanied by hemorrhages in the thigh and pectoral muscles 
(Allan et al., 1972). It causes clinical disease and mortality in chickens 3 weeks of age or 
older. When younger birds are infected, it causes a severe and prolonged 
immunosuppression, leaving them susceptible to many other diseases, such as 
Escherichia coli (E. coli) gangrenous dermatitis, and vaccination failures. Fortunately, 
IBD is not a zoonotic disease and has no public health importance (Lukert and Saif, 
1997).
2.5.1. History of IBD
The first IBD outbreak was reported in Gumboro, Delaware in 1962. In 1957, 
Albert Cosgrove recognized a syndrome, later termed “avian nephrosis” on a broiler farm 
near Gumboro, DE. For this reason the disease is also called “Gumboro disease” 
(Cosgrove, 1962). It was referred to as “avian nephrosis syndrome” due to severe kidney 
lesions found in birds that succumbed to infection (Lukert and Saif, 1997). The presence 
of kidney lesions generated some confusion between IBDV and IBV. This syndrome was 
characterized by 10% morbidity and 1-10% mortality; and it was believed to be a variant 
strain of IBV, called the “Gray strain”. Winterfield successfully isolated IBDV in 
embryonated eggs from birds immune to Gray strain, and having signs of IBD 
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(Winterfield et al., 1962). Several years later, this condition was also detected in other 
regions of the US, such as Mississippi, Alabama, Georgia, and North Carolina. In 1967, 
the first vaccine against Gumboro disease was licensed and named “Bursa Vac®”, which 
was derived from chicken embryos infected with a mild isolate of the virus (Snedeker et 
al., 1967). In 1970, Hitchner proposed the name “infectious bursal disease” for this 
disease, which caused 2% mortality, and severe lesions in the BF, and identified this 
organ as the primary target organ for virus infection (Hitchner et al., 1970).
Allan and collaborators reported that IBDV infection could cause 
immunosuppression in younger birds, leaving them more susceptible to bacterial 
infections, other viral infections, and failure to respond to vaccines (Allan et al., 1972). 
After the discovery of immunosuppression caused by IBDV, researchers realized 
the importance of developing a new vaccine to aid in the control of the disease. The first 
attenuated vaccine for IBDV was made in 1973 from homogenated BF of chickens 
infected with the field isolate. Later, this vaccine was adapted and attenuated in chicken 
embryo fibroblasts (CEF) cells by Lukert and co-workers. 
The immunosuppressive aspect of IBDV was described by Wyeth in 1975, using 
1-day and 3-week-old chickens exposed to IBDV, and challenged with Salmonella 
typhimurium and E.coli (Wyeth, 1975).
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The existence of a second serotype was described in 1980 (McFerran et al., 1980). 
Serotype I viruses are pathogenic to chickens. Serotype II viruses, most commonly 
isolated from turkeys, are apathogenic to chickens. The control of the disease by 
vaccination was compromised when new variants of IBDV were isolated in the US 
(Snyder et al., 1992; Jackwood and Saif, 1987). These new variant strains are called 
Delaware and GLS, which were isolated in Delmarva poultry-producing farms (Snyder et 
al., 1988; Rosenberger and Cloud, 1986). These variant strains can overcome the 
maternal immunity barrier and cause disease in the presence of high levels of maternal 
antibodies, elicited by vaccination with ‘classical’ strains.  These viruses cause rapid 
bursal atrophy without signs of inflammation. Very virulent strains of IBDV, exhibiting 
90% to 100% mortality in infected flocks, were identified in Europe and Asia in the late 
1980s (van den Berg et al., 1991; Chettle et al., 1989).
2.5.2. Pathogenesis 
IBDV can enter the susceptible host by the respiratory, gastrointestinal or urinary 
tracts. The virus exhibits tropism for certain organs and infects specific cell types and 
tissues. During oral infection, IBDV can be detected in macrophages and lymphoid cell 
populations in the cecum, and later on in the duodenum, jejunum, and liver. It enters the 
bloodstream, and spreads to other lymphoid tissues, such as the BF. IBDV has tropism 
for BF and it is the site of a secondary intense viremia (Muller et al., 1979).
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The general symptoms include anorexia, soiled vent feathers, whitish or watery 
diarrhea, trembling, severe prostration, followed by death (Cosgrove, 1962). Chickens 3 
to 6 week-old have completely developed BFs, which increases susceptibility to IBDV 
infections. However, chickens of all ages may become infected by IBDV (Lukert and 
Saif, 1997). Challenge studies using 3-day-old chicks treated with cyclosphosphamide 
and 4-week-old bursectomized chickens showed no clinical signs of disease (Fadley, 
1976). IBDV targets lymphoid B cells in an active state of division and differentiation, 
which bear on their surfaces immunoglobulin M (sIgM) (Burkhardt and Muller, 1987). 
Infection by IBDV results in lysis of these cells, which results in the destruction of the 
bursa.
IBDV pathogenicity is dependent on the strains used. Classical virulent strains, 
such as IM strain, cause hemorrhagic lesions, atrophy of the bursa, and about 30% 
mortality. D78, a classical attenuated strain, causes neither mortality nor gross lesions in 
the bursa. GLS is a variant strain and causes bursal atrophy and immunosuppression, with 
very low mortality. With very virulent viruses, mortality can reach up to 70% with very 
severe bursal damage (Figure 1).
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Figure 1 - Gross bursal lesions caused by different strains of IBDV. The control is a 
normal BF derived from non-infected chicken. Chickens infected with an attenuated 
strain of IBDV (D78) do not exhibit bursal lesions, whereas variant GLS strain causes 
bursal atrophy, and the IM strain causes hemorrhagic lesions. 
BF plays an important role in the avian immune system. It is the primary site for 
B cells differentiation, and maturation (Glick et al, 1991). B cells are antibody-producing 
cells when activated. Therefore, their depletion results in a severe reduction or total 
abrogation of a humoral immune response. Thus, birds infected with IBDV have their 
immunity compromised against other pathogens in the field or vaccines. Birds infected 
with IBDV at day one of age and challenged by NDV virus at one week, two weeks and 
three weeks of age demonstrated severe, moderate, mild humoral immunesuppression, 
respectively (Allan et al, 1972). Avian macrophage cell lineage can also be infected by 
IBDV and it has been implicated in viral dissemination, and disease exacerbation (Inoue 
et al., 1992; Sharma and Lee, 1983). 
Control not infected                         D78 GLS IM
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2.5.3. Epidemiology
IBDV can infect chickens, turkeys, and ducks. Clinical signs of the disease can be 
seen in susceptible chickens between 3 to 6 weeks of age. Birds younger than 3 weeks do 
not exhibit clinical signs of IBD. However, IBDV infection can cause a severe depletion 
of B cells in the BF, leaving them immunosuppressed and susceptible to other 
opportunistic infections (Lukert and Saif, 1997).
IBDV can be spread by contact with infected birds and contaminated fomites, 
such as drinking water, feed, and feces. The virus is stable in poultry houses for a long 
time due to its resistance to many physical and chemical agents. Thus, it can be easily 
carried from one flock to a succeeding flock. Benton and co-workers showed that poultry 
houses with IBDV-infected birds were still infective for other birds 54 and 122 days after 
removal (Benton et al., 1967). IBDV is resistant to some disinfectants. Iodine and 0.5% 
formalin reduce IBDV infectivity and are widely used in the poultry industry. There is no 
evidence to support vertical transmission via eggs or infection via mosquitoes (Lukert 
and Saif, 1997).
2.5.4. Diagnosis of IBD
Acute outbreaks of IBD with characteristic clinical signs, high morbidity, spiking 
mortality and rapid recovery can make a preliminary diagnosis. Confirmation of the 
diagnosis can be made by necropsy examination of the BF, such as enlargement due to 
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inflammation followed by atrophy. BF, spleen and blood samples can be used for viral 
isolation, using 9 to 11-day-old embryos. ELISA procedure is the most commonly used 
serological test for evaluation of IBDV antibodies and its results are comparable to VN 
(Lukert and Saif, 1997). Reverse transcriptase-polymerase chain reaction (RT-PCR) can 
also be used to confirm the preliminary diagnosis (Jackwood and Sommer, 1999). 
2.5.5. Prevention and control
IBDV can survive for long periods of time in the environment and can easily be 
spread from one flock to another. Thus, strict biosecurity measures are required. 
Vaccination of broiler breeders to boost and prolong immunity is a common practice. 
This vaccination regime can confer maternal immunity to the progeny in the first few 
weeks of life. In vaccination program breeders are heavily vaccinated with live 
intermediate, and intermediate plus vaccines, as well as killed vaccines containing classic 
and antigenic variant viruses. Live attenuated vaccines are produced in tissue culture or 
chicken embryos and can be administered via drinking water or eye drop to breeder 
pullets. Inactivated vaccines are effective in producing high levels of antibodies in 
breeder hens, which can pass along via yolk to their progeny (van den Berg et al., 1991). 
Unfortunately, oil-emulsion inactivated vaccines have to be administered manually by 
intramuscular injections. This methodology is not very effective because as the hen ages, 
the level of immunity passed to the progeny reduces (Lukert and Saif, 1997).
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To overcome this problem, the poultry industry routinely vaccinates young broiler 
chicks, in cases where IBDV is endemic (Lukert and Saif, 1997). One of the most 
important drawbacks of live attenuated vaccines is determining the optimal time for 
vaccination of young chicks because maternal antibodies can interfere with vaccine 
efficacy.  Incomplete attenuation of IBDV can leave residual pathogenicity in live 
vaccines. In addition, there is always a risk of reversion from attenuated to virulent forms 
of IBDV in the field. IBDV strains of intermediate virulence present a higher residual 
pathogenicity, even though they are unable to break through the maternal antibodies, and 
induce strong immune response. Highly attenuated strains used for vaccination may lose 
virulence and reduce the severity of bursal lesions. However, these vaccines may not be 
able to overcome the maternal antibody barrier in order to establish immunity.
A new generation of vaccines against IBDV has been developed in conjunction 
with new advances in molecular biology and recombinant DNA technologies. VP2 is the 
major immunogenic protein of IBDV and it induces virus-neutralizing antibodies. Several 
studies demonstrated the protective potential of VP2 protein when expressed in yeast 
(Macreadie et al., 1990), adenovirus (Francois et al., 2003), FPV (Bayliss et al., 1991), 
HVT (Tsukamoto et al., 2002; Darteil et al, 1995), and in insect cells by the baculovirus 
system (Vakharia, 1997; Snyder et al., 1994; Vakharia et al., 1993). The baculovirus-
expressed proteins of GLS-IBDV fully protected chickens immunized at 6 weeks and 
boosted at 8 weeks of age against GLS and Delaware variant strains, and partially 
protected against standard challenge strain STC (Vakharia et al., 1993). In another study, 
the baculovirus expressed-proteins from a chimeric GLS/D78 construct also protected 
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chickens against STC challenge (Snyder et al., 1994).  Virus-like-particles (VLPs) 
produced by the baculovirus system was also used as a vaccine that provided protection 
against challenge with variant (E/Del and GLS), and classical strains of IBDV (Vakharia, 
1997). HVT was used as a vector to express VP2 protein, which conferred immunity 
against challenge strains (Tsukamoto et al., 2002). More recently, Francois and co-
workers expressed VP2 protein in a type 1 fowl adenovirus (chicken embryo lethal 
orphan virus). This recombinant virus was apathogenic to chickens inoculated by several 
routes, including in ovo with different dosages. No clinical signs or mortality were 
observed after challenge with a very virulent IBDV (strain 89-163) in vaccinated 
chickens using subcutaneous or intradermic routes. Birds vaccinated in ovo were also 
protected (Francois et al., 2003).
2.6. Infectious bursal disease virus 
2.6.1. Virion 
IBDV belongs to Avibirnavirus genus of the Birnaviridae family and all viruses in 
this family contain two segments of double-stranded RNA (Dobos et al., 1995; Kibenge 
et al., 1988; Dobos et al., 1979). There are two other genera in this family, 
Aquabirnavirus and Entomobirnavirus. Viruses in the Entomobirnavirus genus include 
Drosophila X virus (DXV) of fruit fly. The Aquabirnavirus genus includes IPNV that 
infects fish, Tellina virus (TV), and oyster virus (OV). The virion is non-enveloped and 
made up of single-shelled icosahedrons of approximately 55-60 nm in diameter, having a 
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T=13 symmetry as shown in Figure 2 (Bottcher et al, 1997). The virion capsid is 
constituted of VP2 protein (51%), VP3 (40%), VP4 (6%), and 3% of VP1 (Kibenge et al., 
1999; Dobos, 1979). 
Figure 2 - Three-dimensional map of IBDV virion indicating a T=13 architecture. A 
close-up view down on the threefold axis of the particle. Graphics adapted from Bottcher 
et al., 1997.
2.6.2. Genome 
IBDV genome contains two double-stranded RNA segments, A and B (Figure 3). 
Segment A is 3261 nt in length with two overlapping reading frames (ORF). The larger 
ORF encodes one polyprotein (VP2-VP4-VP3) of 1012 amino acids (Hudson et al., 1986; 
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Azad et al., 1985). The smaller ORF encodes one 17 KDa NS protein with 145 amino 
acids (Mundt et al. 1997; Spies et al., 1989). The smaller segment B is 2827 nt long. It 
contains only one ORF, which initiates at 112 nt from the 5’ end and encodes VP1, an 
879 amino acid protein with molecular weight of 94 KDa.
Figure 3 – Schematic organization of the IBDV genome. Segment A encodes mature 
viral proteins VP2, VP4, and VP3, and VP5 (NS protein). Segment B encodes a 94 KDa 





























VP4 is a viral protease responsible for the cleavage of the polyprotein VP2-VP4-
VP3 (Figure 3). Electron microscopy of the external surface of the capsid demonstrated 
that VP2 (42 KDa) is the major structural protein of IBDV and it forms trimeric subunits 
(Bottcher et al., 1997). The VP2 protein has serotype-specific group antigens responsible 
for antigenic variation between serotypes and strains. It is also the major antigen 
recognized by the host immune system (Fahey et al., 1989; Becht et al., 1988).
VP3 also forms trimeric subunits, which build up the internal surface of the 
capsid. This protein is the second largest structural protein of IBD virion (32 KDa) 
(Bottcher et al., 1997). VP3 also contains group-specific antigen (Becht et al., 1988). VP3 
protein appears to bind with dsRNA and may be involved in viral assembly and 
replication (Tacken et al., 2002).
VP4 is a 28 KDa protein involved in the proteolytic autoprocessing of polyprotein 
(VP2-VP4-VP3). It has been demonstrated that VP4 is also involved in the formation of 
tubules (type II) in the cytoplasm of IBDV-infected cells (Granzow et al., 1997).
VP5 is a non-structural protein, which is present in infected cells and not in 
virion. The function of VP5 is not clearly understood. However, recent studies have 
shown that VP5 is not essential for virus replication, and the VP5-deficient virus can 
replicate in vitro and in vivo (Yao et al., 1998; Mundt et al., 1997). Moreover, this mutant 
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virus was attenuated and grew to lower titers than wild-type virus. Growth of the mutant 
in cell culture demonstrated reduced CPE. In vivo studies infecting chickens with the VP5 
knockout virus did not cause gross microscopic lesions in the BF (Yao et al., 1998). 
The RdRp (VP1) is a 90 KDa protein with several functions, such as replicase 
activity, guanylyltransferase activity, and capping activities (Spies and Muller, 1990; 
Spies et al., 1987). VP1 is present in the virion as a free polypeptide and as a genomic-
linked protein (VPg), bound to the 5’ ends of both genomic segments A and B (Dobos et 
al., 1995; Muller and Nitschke, 1987).
2.6.4. Viral replication
Attachment to the host cell membrane is the first step for viral replication to take 
place. It requires the interaction of the virion with a cell membrane receptor. The specific 
cell receptor for IBDV is not known. It seems that VP2 is responsible for interactions 
with cell receptor and this receptor may be composed of N-glycosylated protein present 
in sIgM-bearing B-lymphocytes (Ogawa et al., 1998; Nieper and Muller, 1996). After cell 
entry, the virus particle must be uncoated for further genome release.
After attachment, IBDV enters the cell and may initiate transcription and 
replication without uncoating (Spies et al., 1987). Replication and assembly take place in 
the cytoplasm of infected cells. IBDV replication occurs in a semi-conservative way, 
where the newly synthesized strand remains attached to its template. The positive-strand 
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RNA is packaged to make new viral particles. Finally, the negative-strand RNA is 
synthesized within the newly formed viral particle to complete the formation of dsRNA 
(Patton and Spencer, 2000). The new assembled virus particle is released to the 
extracellular compartment by host cell lysis and apoptosis (Yao and Vakharia, 2001; 
Lombardo et al., 2000; Fernandez-Arias et al., 1997).
2.7. DNA vaccines
Wolff and co-workers were first to apply the concept of DNA vaccines, also 
called the “third vaccine generation”. They found that inoculation of chloramphenicol 
transferase (CAT), luciferase, or beta-galactosidase genes into the muscle of mice 
generated protein expression in this tissue (Wolff et al., 1990). The host immune system 
could recognize this expressed protein as foreign and mount an immune response against 
it. Thus, the idea of a DNA vaccine was generated (Cox et al., 1993; Ulmer et al., 1993; 
Tang, 1992).
Over the past years, research on DNA vaccination has expanded and many studies 
have been published. This technique consists of the insertion of DNA sequences 
encoding the protein (or proteins) of interest into a eukaryotic expression vector (EEV). 
Bacteria (in most cases, E. coli) are transformed by the plasmid DNA, grown in large 
scale, and the amplified plasmid DNA is purified for further inoculation into the animal 
to be vaccinated. Host cells then express the plasmid DNA, and the protein produced by 
the vaccinated animal elicits an immune response (Robinson, 1997; Tang, 1992). DNA 
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vaccines have been shown to elicit both humoral and cellular immunity, which provide 
protection from viral challenge (Kowalczyk and Ertl, 1999).
Several different methods and routes can be used to deliver DNA vaccines. 
Needle-injection into muscle tissue and into the skin is the most commonly used method. 
Gene-gun delivery of a DNA vaccine is used to transfect skin cells, which requires 
extremely small amounts of plasmid DNA. The disadvantages of this delivery method are 
that it requires hair removal in the inoculation site and its costs are prohibitive for large-
scale vaccination. 
The exact mechanism of how DNA vaccines initiate an immune response is not 
clearly understood. One hypothesis is that after intramuscular injection, the plasmid DNA 
enters the host cell and is then transcribed in the nuclei. The mRNA is translated into 
proteins in the cytoplasm. The new synthesized protein is processed, transported, and 
presented to the host immune system, initiating both humoral and cell-mediated 
immunity in a similar mechanism used by viruses. During transport and processing, these 
peptides are associated to MHC-I molecules and presented on the surface of the cell. T 
cell receptor (TCR) recognizes peptides associated with MHC-I molecules and these cells 
become activated (Babiuk et al., 2000). 
DNA vaccines have also been shown to initiate humoral responses, leading to 
protection against viral diseases in animals (Dufour, 2001). In some cases, protection 
against challenge was achieved even though antibodies were not detected, indicating the 
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presence of cell-mediated immunity (CMI) (Kowalczyk et al., 1999). Protection using 
DNA vaccines has been evaluated in many different viruses (Donnelly and Ulmer, 1999), 
bacteria (Strugnell et al., 1997), and protozoa (Kalinna, 1997).
2.7.1. DNA vaccine advantages
One of the most important advantages of DNA vaccines is their safety. They 
cannot revert to virulent forms, as seen in live attenuated virus vaccine (Corr et al., 1996). 
DNA vaccines have a much longer shelf life than vaccines that consist of live viruses. 
These vaccines do not require the propagation of virulent strains of viruses nor constant 
refrigeration, and are easy and inexpensive to produce (Beard and Mason, 1998). Their 
use in animals with circulating maternal antibodies has been investigated with promising 
results (Babiuk, 1999). 
2.7.2. DNA vaccines in poultry
The literature shows several reports of the use of DNA vaccines in poultry. Most 
of them investigated the route, dosage, promoters, and formulation of the DNA vaccine 
for optimal delivery and protection. 
The first studies that used nucleic acid vaccines in poultry examined the responses 
to avian influenza virus. One study evaluated the protective response against a lethal 
virus challenge in chickens that were vaccinated by plasmid DNA containing 
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hemagglutinin 7 gene (H7). Three-week- old chickens were inoculated intramuscularly, 
intravenously, and intraperitonially with 100 µg of H7 plasmid DNA. After 4 weeks, the 
birds were boosted with 300 µg of plasmid, using all three-immunization routes. One 
week post secondary vaccination, birds were challenged with a virulent avian influenza 
virus of the H7 subtype. Vaccinated birds showed 60% protection. DNA vaccinated birds 
showed minimal humoral responses after vaccination, which were elevated after 
challenge (Fynan et al., 1993). A similar study was carried out by Robinson and co-
workers, which gave almost the same results (Robinson et al., 1993).
Additional studies were carried, which evaluated four different promoters that 
express hemagglutinin protein of H5 influenza virus: immediate early cytomegalovirus 
(CMV), Rous sarcoma virus, chicken actin, and simian virus 40 (SV-40). Only the 
plasmid DNA containing CMV promoter generated an antibody response in one-day-old 
chicks vaccinated intramuscularly. Birds in this group were boosted at three weeks of 
age, which resulted in partial protection. Plasmid containing CMV promoter was also 
used to examine the beneficial effect of possible vaccine adjuvant, such as 25% sucrose, 
diethylaminoethyl (DEAE) dextran, calcium phosphate, polybrene (hexadimethrine 
bromide), and two cationic lipids (lipotaxi and lipofectin) to help increase the uptake of 
the vaccine. Better results were obtained with the cationic lipids (Suarez and Schultz-
Cherry, 2000).
One attempt to control coccidiosis also employed the use of a DNA vaccine, 
which was prepared by cloning the Eimeria gene. Intramuscular and subcutaneous 
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injections of 5 to 100 µg of plasmid DNA were injected into one-day-old chickens two 
weeks apart. Results from Eimeria acervulina challenge showed that two injections with 
higher amounts of DNA were more effective than one dose in reducing oocysts. 
Intramuscular injection resulted in higher levels of serum antibodies when compared to 
subcutaneous route. Also significant changes in T cell profiles were observed, indicating 
that this DNA vaccine can initiate local and systemic responses against Eimeria (Song et 
al., 2001).
Potential DNA vaccines for IBDV have also been studied. Fodor and his 
collaborators evaluated the efficacy of two plasmid DNA vaccines in chickens, one 
encoding the VP2 gene and the other encoding the polyprotein (VP2-VP4-VP3) genes. 
DNA vaccine containing the VP2 gene did not induce humoral responses or protection 
against challenge but groups vaccinated with VP2-VP4-VP3 genes produced antibodies 
and 36% protection against IBDV (Fodor et al., 1999). Another IBDV study also 
evaluated the VP2-VP4-VP3 genes for use as a DNA vaccine, which was administered 
intramuscularly with one or two booster injections. Vaccinated chickens showed no 
clinical signs or mortality following IBDV challenge (Wu et al., 2000).
One IBV study was conducted with plasmid DNA vaccine encoding the 
nucleocapsid gene. Vaccinated birds were protected against challenge. However, no 
antibody response was detected and protection was attributed to cytotoxic T cell 
responses (CTL) (Seo et al., 1997). Sakaguchi and co-workers evaluated two plasmid 
DNA vaccines against NDV (linear and circular form). Protection from lethal dose of 
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NDV was observed in birds that received a mixture of both forms of the plasmid 
expressing the F gene (Sakaguchi et al., 1996).
The concept of in ovo delivery of plasmid DNA vaccines remains novel for most 
diseases. Only few reports are described. In one study, a DNA vaccine was prepared for 
IBV, which was delivered in ovo. Complete protection (100%) was conferred in birds 
vaccinated in ovo and then boosted at 2-weeks of age with live attenuated vaccines. Birds 
that were immunized with only the DNA vaccine or live attenuated vaccine showed less 
than 80% protection. This report is the first to suggest the use of a DNA vaccine to prime 
the immune system (Kapczynski et al., 2003).
More recently, Oshop and co-workers developed a modified in ovo delivery 
technique, which one can deliver the DNA vaccine to the embryo (Oshop et al., 2003; 
Oshop et al., 2002).
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CHAPTER 3
EVALUATION OF IN OVO DELIVERY SYSTEM 
FOR PLASMID DNA VACCINATION 
ABSTRACT
In ovo vaccination against Marek’s disease virus (MDV) is a common practice in 
more than 85% of broilers produced in the US. DNA vaccines represent a new tool to 
prevent infectious diseases in many species, including poultry. An in ovo delivery system 
for plasmid DNA vaccines is described in which we evaluate the route of delivery (air 
cell vs amniotic cavity), transfection reagent (IFA+DMSO vs polyethylenimine), dose of 
plasmid DNA (1 to 100 µg/egg), and the nature of humoral immune responses.  
A plasmid DNA (CMV-EGFP-BGH) construct expressing enhanced green 
fluorescent protein (EGFP) under cytomegalovirus (CMV) immediate early promoter was 
used to optimize the route of delivery, and formulation for in ovo DNA vaccination. A 
plasmid expressing the hemmagglutinin-neuraminidase (HN) gene of Newcastle disease 
virus (pIRES-HN-EGFP) was used to evaluate five different dosages of DNA and the 
humoral immune responses after in ovo vaccination.
- 53 -
Higher expression of EGFP and hatchability were obtained when 18-day-old 
embryos were inoculated through the amniotic cavity using a cationic lipid adjuvant 
containing polyethylenimine (PEI - ExGen®). Transgene expression was observed even 
when low amounts of plasmid DNA were used (1 µg/egg). A dose-dependent response 
was observed with plasmid DNA concentrations of 1, 10, 25, 60, and 100 µg/egg.  Better 
responses were detected when embryos were inoculated with 60 µg of plasmid DNA. 
Detectable humoral responses were observed as measured by ELISA and isotype-ELISA 
assays.
INTRODUCTION
In the 1990s, an entirely new type of vaccine (DNA vaccines) was first described 
(Robinson et al., 1993; Ulmer et al., 1993; Wolff et al., 1990). These new vaccines used 
naked plasmid DNA to express foreign proteins in the host. DNA vaccines are specially 
modified bacterial plasmids that usually have an Escherichia coli origin of replication, an 
antibiotic resistant gene, and eukaryotic promoter that drives the expression of the target 
gene, a target gene, and a polyadenylation signal sequence. The target gene is usually an 
antigenic protein from a pathogenic infectious organism. The plasmid DNA is commonly 
delivered either by intramuscular injection or with the use of a gene-gun that forces the 
DNA into epidermal cells. 
Since these initial reports on this novel vaccine technology, DNA vaccines have 
been successfully used to immunize a number of different animal species against a
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multitude of infectious agents (Sakaguchi et al., 1996; Corr et al., 1996; Scholz et al., 
1993; Fynan et al., 1993). DNA vaccines have also been successfully used in poultry to 
immunize against several pathogens (Sakaguchi, 1996; Fynan et al., 1993; Robinson et 
al., 1993). Many of these experimental procedures used large amounts of plasmid DNA 
in several applications. These methods employ impractical delivery systems, such as by 
gene-gun or intramuscular injections, which currently are not suitable for administration 
to large numbers of birds in a cost effective manner. 
In order to be suitable for poultry, DNA vaccines have to be easily administered 
to large numbers of animals at the same time. The air cell route for in ovo delivery of 
plasmid DNA was examined previously, and protein expression was demonstrated in the 
embryo using the chloramphenicol acetyl transferease (CAT) reporter gene (Oshop et al., 
2003). Several eukaryotic expression vectors with different promoters have been 
evaluated, and all avian studies reported higher levels of expression when using human 
cytomegalovirus immediate early promoter/enhancer (CMV) (Oshop et al, 2003; 
Kapczynski et al., 2003; Suarez et al, 2000; Akiyama et al., 1994; Scholz et al., 1993). 
Plasmid DNA can be easily degraded after delivery by host endonucleases (Lewis 
and Babiuk, 1999). In order to protect and enhance plasmid DNA expression, many 
attempts to develop an adjuvant have been made. Calcium phosphate, diethylaminoethyl 
(DEAE) dextran, 25% sucrose, polybrene (hexadimethrine bromide), and two cationic 
lipids (lipotaxi and lipofectin) were evaluated as adjuvants to an avian influenza DNA 
vaccine when injected into the muscle of one-day-old chicks.  Lipotaxi and lipofectin 
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induced better antibody responses (Suarez et al, 2000). In addition, two possible 
adjuvants for in ovo DNA vaccination, neutral lipid incomplete Freund’s adjuvant (IFA) 
mixed with dimethylsulfoxide (DMSO), and a cationic lipid (LipofectAmine Plus®), 
were also evaluated. Better results were obtained by IFA mixed with 50% DMSO (v/v) 
(Oshop et al., 2003). Another study done in vitro suggests the use of PEI (ExGen®) to 
obtain optimal transgene expression (Heckert et al., 2002).
Another important aspect to be evaluated is the dose of plasmid DNA required to 
obtain high protein expression. Earlier studies (Oshop et al., 2003; Suarez et al., 2000) 
observed a dose-dependent response using one-day-old chicks and 18-day-old embryos, 
respectively. Suarez and co-workers used 10, 50, 100, and 250 µg of pCI-neoHA/bird 
intramuscularly. A maximum response was observed when 100 µg of plasmid was used 
(Suarez et al., 2000). In ovo inoculation studies by Oshop and collaborators, reported 
better responses using 60 µg of plasmid (Oshop et al., 2003). 
Several studies in recent years addressed the nature of plasmids, such as promoter 
and polyadenylation signals (Kapczynski et al., 2003; Oshop et al., 2003; Heckert et al., 
2002; Suarez et al., 2000). Several routes for optimal plasmid DNA delivery, such as 
intramuscular (Heckert et al., 2002; Fodor et al., 1999), transcutaneous (Heckert et al., 
2002), and in ovo (Oshop et al., 2003; Kapczynski et al., 2003) were examined. There are 
few reports regarding the dose of plasmid DNA vaccine for optimum transgene 
expression and protection efficacy (Oshop et al., 2003; Heckert et al., 2002; Suarez et al., 
2000; Sakaguchi et al., 1996).
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There are only a few studies that address the issue of in ovo delivery of DNA 
vaccines in chickens. Therefore, the present study was designed to address several 
parameters to optimize in ovo DNA vaccination in chickens. This study has several 
objectives. We will compare the air cell route previously examined for plasmid DNA 
vaccination and the amniotic cavity, the route routinely used by the poultry industry to 
deliver Marek’s vaccine. We also propose to determine the most efficient transfection 
reagent for in ovo DNA vaccines (IFA+DMSO vs PEI-ExGen®). Another important 
aspect addressed in this chapter is the dose of DNA vaccine for in ovo inoculation. We 
also evaluate the humoral immune responses of DNA vaccine expressing the HN gene of 
NDV, after in ovo delivery.
MATERIALS AND METHODS
3.1. Construction of plasmid DNAs
To evaluate route and formulation for in ovo DNA delivery, we used a plasmid
CMV-EGFP-CAT- BGH, a gift from Dr. Subbiah Elankumaran (Heckert et al., 2002). 
Cloning procedures were carried out essentially as described (Sambrook et al., 1989). 
Briefly, the CAT gene was removed by digestion with ApaI and NotI restriction enzymes. 
The DNA fragment was excised from a 1% agarose gel and re-ligated. E.coli (DH5α) 
were transformed and recombinants were plated on ampicillin plates. Plasmid DNA was 
prepared and purified using endotoxin-free silica column kits (Qiagen, Inc., Valencia, 
CA) as per manufacturer instructions. The plasmid DNA preparation was checked on 1% 
- 57 -
agarose gel (w/v) for genomic DNA or RNA contamination. The plasmid concentration 
was determined by spectrophotometer reading (260 nm). The plasmid DNA was frozen at 
–20°C to protect it from degradation by endonucleases.
The last two studies utilized the pIRES-EGFP vector in which the HN gene of 
NDV (Beaudette strain) was inserted to generate the pIRES-HN-EGFP plasmid. Briefly, 
Vero cells were infected with NDV at a multiplicity of infection (MOI) of 0.01. Three 
days after infection, viral RNA was extracted and used as template for RT-PCR. The 
coding sequence of HN consisting of 2265 base pairs was amplified using two specific 
primers that introduced BglII and SacII restriction enzyme recognition sites (respectively 
underlined) at the 5’ and 3’ end of the NDV HN antigenomic RNA. Primers used were: 
forward 5’-AAGATCTATGGACCGCGCAGTTAGCCAAGTTG-3’ and reverse 5’-
ACCGCGGTACTAACCAGACCTGGCTTCTCTAAC- 3’. RT-PCR product was excised 
from 1% agarose gel using a QIAquick gel extraction kit (Qiagen Inc., Valencia, CA). 
The PCR product was ligated into a pCRII-TOPO vector using the Topo cloning kit 
(Invitrogen). After ligation, E.coli cells were transformed and white colonies bearing the 
inserted HN gene were selected for plasmid preparation. Plasmid was digested with BglII 
and SacII restriction enzymes. HN gene fragment was recovered after gel purification and 
then ligated between BglII and SacII sites of pIRES-EGFP vector (Figure 4). E.coli cells 
were transformed and the recombinants selected after plating. The resulting plasmid was 
designated pIRES-HN-EGFP. The inserted DNA was sequenced to confirm the identity 
of the HN gene. Large amounts of purified, endotoxin-free plasmid were obtained from 
Aldevron, Inc. (Fargo, ND).
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Figure 4 – Schematic diagram of a 5.3Kb eukaryotic expression vector used to 
express HN protein. NDV-HN gene was inserted in the multiple cloning sites (MCS). 
Independent EGFP expression was possible due to the presence of internal ribosomal 
entry site (IRES) downstream of MCS.
3.2. In vitro transfection
The plasmid CMV-EGFP-BGH was evaluated in vitro using HD11 (avian 
macrophage cell line) cells to test its transfection capability as described (Heckert et al., 
2002). Briefly, HD11 cells were transfected with 5 µg of plasmid DNA using 
LipofectAmine (Invitrogen). After 24 h incubation, cells were examined under a Nikon 
Eclipse TE epifluorescent microscope to detect EGFP.
The plasmid pIRES-HN-EGFP (5 µg) was used to transfect Vero cells using 
Lipofectin (Invitrogen, Grand Islands, NY). Protein expression was observed by 
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immunostaining techniques. Briefly, after transfection Vero cells were washed three 
times with phosphate buffered solution (PBS), and fixed with acetone and methanol (v/v) 
for 20 min. Vero cells were washed twice, and incubated with polyclonal chicken anti-
NDV antibody (1:20) for 1.5 h at RT. Cells were then washed three times, and goat anti-
chicken IgG peroxidase labeled antibody (1:50) was added, and plates were further 
incubated at RT for 30 min. Cells were washed three times, and 200 µl/well of 
Trueblue® (Kirkegaard & Perry Lab., Gaithersburg, MD) peroxidase substrate was 
added. After 15 min, Trueblue® excess was rinsed and cells were examined under the 
microscope. 
Experiment 1 – In order to determine route and formulation to be used for plasmid DNA 
delivery, five groups (of at least 10 eggs each), were inoculated into the air cell and 
amniotic cavity with 60 µg/egg of CMV-EGFP-BGH. A preliminary trial to test the 
amniotic cavity delivery technique was performed using Indian ink. After dye 
inoculation, embryos were chilled and opened to inspect the site of inoculation. For air 
cell inoculations, pre-trials were considered unnecessary. All embryonated eggs used in 
these experiments were from white leghorn hens, 18 days of embryonation, SPF 
(SPAFAS Inc, Norwich, Ct., USA) and were incubated at 100ºF with 60-80% humidity, 
as indicated by the thermometer (dry bulb) and hygrometer (wet bulb), respectively. For 
either route of inoculation, a small hole was made in the large end of the egg. The air cell 
inoculation was performed by dropping the plasmid DNA formulation on top of the
chorioallantoic membrane, using a 25 gauge, 2.5 cm needle and only half of the needle 
length was allowed to penetrate the eggshell. Inoculations into the amniotic cavity were 
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performed using a 23 gauge, 2.5 cm needle, accordingly to preliminary trials described 
previously.
The ExGen® formulation consisted of 60 µg of plasmid CMV-EGFP-BGH 
diluted into sterile glucose solution (5%) and six equivalents of the cationic polymer gene 
delivery reagent (ExGen®500 in vivo transfection, MBI Fermentas). The second 
formulation tested (Oshop et al., 2003), consisted of 60 µg of plasmid DNA combined 
with IFA, forming a mixture of 50 µl, and mixed vigorously. The same amount of DMSO 
(Sigma, USA) was added and the mixture was sonicated. One control group consisted of 
10 eggs that were un-inoculated.
After inoculation, all eggs were sealed with tape and re-incubated. Right before 
hatch, eggs were placed at 4ºC to induce death by hypothermia. Tissues such as liver, 
lung, spleen, muscle, intestine, and heart were collected. Tissues were placed in 
TissueTek OCT Compound (Sakura, Inc.) and snap frozen in liquid nitrogen. The 
samples were then stored at –70°C until processing. Frozen tissues sections were cut at 8 
µm thickness with Leitz HM-500 Cryostat, air-dried at RT, fixed in acetone for 20 min, 
and mounted into glass slides with PBS/glycerol (v/v). Tissues samples were then 
microscopically examined under a UV light (488 nm excitation) at 40, 100, 400X 
magnification.
Experiment 2 - Having determined the most effective route for in ovo plasmid delivery 
as well as formulation, this experiment was designed to evaluate the dosage of pIRES-
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HN-EGFP DNA to obtain higher levels of protein expression. Plasmid DNA was mixed 
with ExGen® in five different dosages (1, 10, 25, 60, 100 µg/egg) and injected into the 
amniotic cavity. Fifteen eggs were used per dose tested. One control group was used, 
consisting of plasmid DNA without HN insert (backbone pIRES-EGFP). Right before 
hatch, all eggs were placed in the refrigerator to induce death by hypothermia. Spleens 
were removed aseptically from each embryo. 
Experiment 3 - This study was designed to evaluate immune responses elicited by in ovo
injection of pIRES-HN-EGFP vaccine construct. Eggs were inoculated with 60 µg/egg of 
plasmid DNA mixed with ExGen® by the amniotic cavity as described in Experiment 1. 
Group 1 was inoculated with pIRES-HN-EGFP; group 2 received the plasmid DNA 
backbone control, and a third group was left un-inoculated. Eggs were sealed and 
incubated until hatch. All feather-dried hatched chicks were transferred directly from the 
hatcher to biological level 2 (BL2) animal facility in Avrum Gudelsky Veterinary Center 
and housed in isolation chambers with ad libitum access to feed and water. At three 
weeks of age, all three groups were sampled for serum, and tears. Tears were collected as 
described (Elankumaran et al., 1996) by applying a pinch of salt to each eye. At five 
weeks of age all birds were anesthetized using isoflurane, and 3-6 mL of blood was 
collected by cardiac puncture. The birds were then humanely euthanized.
- 62 -
3.3. Flow cytometry analyses
To determine dosage of plasmid DNA needed for high protein expression, the 
spleens from birds inoculated with pIRES-EGFP were macerated and filtered through 
sterile 70 µm nylon cell strainers (Falcon, Becton Dickinson Labware, NJ). Cells were 
washed three times with 5 mL of sorter buffer (Hanks balanced salt solution w/o phenol 
red, 3% FBS, 1% sodium azide) for 5 min, 42 xg at 4ºC and resuspended in sorter buffer. 
Viable cells were counted by trypan blue dye exclusion method. A cocktail of NDV 
monoclonal antibodies (62.5 µl of MAb10D11 and 62.5 µl of MAb 15C4 in 12.37 mL of
sorter media) was added (100 µl) to the cells and incubated on ice for 40 min. After two 
washes, cell pellet was resuspended in 2 mL of sorter buffer and 100 µl of goat anti-
mouse IgM+IgG+IgA R-phycoerythrin (PE) labelled (1:500) (SouthernBiotech, Inc., 
Birmingham, AL) was added. Cells were incubated on ice for 30 min, washed twice and 
resuspended in 1 mL of sorter buffer. Analyses were performed using an EPICS XL-
MCL flow cytometer.
3.4. Serology 
Humoral immune responses to HN protein were measured by ELISA (Synbiotics, 
San Diego, CA), isotype ELISA and HI. To verify specific antibody isotype (IgG, IgA, 
and IgM), serum and tear samples were analysed by a sandwich ELISA as described 
(Elankumaran et al., 2002). Briefly, ninety-six well ELISA plates of high adsorption 
capability (Nunc Maxisorb Immunoplate) were coated with affinity purified goat-anti-
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chicken IgG, IgA, or IgM (Bethyl Laboratories, Inc.) antibodies (100 µl/well) diluted 
1:200 in carbonate/bicarbonate buffer (0.1M pH 9.6). The plate was then incubated at 37 
°C for 1 h. After five washes with PBST (PBS, 0.05% Tween-20) plates were dried, and 
blocked for 1 h at RT with 1% BSA in PBST. Serum and tear samples were diluted 1:50 
in dilution/blocking buffer (Kirkegaard and Perry Laboratories Inc., Gaithersburg, MD) 
and 100 µl of each sample was added to the appropriate wells. Each sample was run in 
duplicate. Anti-NDV chicken polyclonal serum (1:50) was used on each plate to serve as 
positive control. Normal chicken polyclonal serum (1:50) was diluted and used as a 
negative control. The plates were then incubated at RT on a plate shaker for 1 h. After 
incubation, plates were washed five times and incubated with NDV (1:200) at RT for 30 
min. Each sample was tested with each antibody isotype, separately. Monoclonal 
antibodies to NDV (10D11, and 15C4) were diluted (1:200) and added to each well. After 
30 min incubation and five washes, goat-anti- mouse peroxidase (Kirkegaard and Perry 
Laboratories Inc., Gaithersburg, MD) was added (100 µl). The plate was then incubated 
for 30 min at RT and washed five times. The substrate TMB (100 µl) (Kirkegaard and 
Perry Laboratories Inc., Gaithersburg, MD) was then added to each well and incubated at 
RT for 10 min. The color reaction was terminated by the addition of 100 µl of sulphuric 
acid (2M). Absorbances were read at 450 nm (reference wavelength of 550 nm). The S/P 
ratios were calculated for each sample.  
HI was performed using 4 hemagglutination units (HAU). Briefly, serum samples 
were two-fold diluted in V-botton-96 well plates, and incubated with 4 HAU of the 
titered antigen (NDV) at RT for 30 min. After incubation, 25 µl of 1% chicken RBC’s 
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were then added to each well. After 40 min incubation, the HI titer was determined as the 
highest dilution of serum causing inhibition of hemagglutination.
3.5. Statistical analysis
Results obtained from Experiment 1, 2 and 3 were statistically analyzed using the 
Student t-test (Statistix, version 7.0). Experimental group means were considered 
significantly different from each other if p<0.05.
RESULTS
3.6. In vitro expression
In order to confirm that CMV-EGFP-BGH plasmid expressed the reporter gene 
(EGFP), HD11 avian macrophage cells were transfected and observed under UV light. 
Our transfection experiments demonstrated the expression of EGFP gene by this 
construct (Figure 5).
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Figure 5 – HD11 avian macrophage cells transfected with plasmid CMV-EGFP-
BGH. A) mock-transfected cells; B) cells visualized under UV light 48 h post-
transfection with 5 µg of plasmid DNA (magnification 100X).
HN expression by pIRES-HN-EGFP was confirmed by the transfection of Vero 
cells and immunostaining technique (Figure 6).
Figure 6 – In vitro expression of HN protein in Vero cells after transfection with 
pIRES-HN-EGFP. Cells were transfected with 5 µg of plasmid using LipofectAmine 
transfection reagent. Cells were immunostained with polyclonal chicken anti-NDV, 
labeled with goat anti-chicken peroxidase, and stained with Trueblue® (Kirkegaard & 
Perry Lab., Gaithersburg, MD). A) mock-transfected Vero cells (negative control); B)




3.7. In vivo EGFP expression after in ovo injection
Tissue distribution of EGFP expression is shown in Figure 7. EGFP expression 
was detected in all tissues examined. The only two exceptions were the spleens of 
embryos inoculated by the air cell with ExGen® and intestine of embryos inoculated 
through either route with IFA+DMSO. Significantly (p<0.05) higher expression was 
observed in the muscle of embryos inoculated by the amniotic cavity using ExGen®. In 
this group, the percentages were 64, 40, 14, 25, 35, and 12% in the muscle, lungs, liver, 
spleen, heart, and intestine, respectively. Lower percentages of expression were observed 
in tissues from embryos inoculated by the air cell using either formulation. Also, lower 
percentages of expression were observed when plasmid DNA was delivered into the 
amniotic cavity using IFA + DMSO. Muscle and lung tissues consistently showed higher 
level of expression irrespective of the route or formulation used.  
With IFA+DMSO formulation, 48 and 52% of embryos pipped when inoculated 
through the amniotic or air cell route, respectively. In contrast, eggs inoculated with 
ExGen® formulation for DNA delivery, 93% and 97% of the eggshells pipped, when the 
air cell and amniotic cavity routes were used. These results indicate that either IFA or 










































Figure 7 – Tissue distribution of EGFP expression from embryos inoculated with 
plasmid pCMV-EGFP-BGH DNA (60 µg/egg) through air cell and amniotic cavity 
using two different formulations (IFA+DMSO and PEI-ExGen®). All embryos were
inoculated at 18 days of embryonation. Tissues were collected prior to hatch and 
examined under UV light. * Significantly different from all other tissues (p<0.05).
3.8. Flow cytometry
Five different doses of the plasmid pIRES-HN-EGFP were inoculated in ovo into 
the amniotic cavity of 18-day-old embryos. The spleens were harvested and processed for 
flow cytometry. Results are shown on Figure 8. Higher percentages of HN labelled cells 
(9.8%) were determined in the groups inoculated with 10 and 25 µg/egg. However these 
groups also had a high standard deviation (SD= 6.53 and 3.85, respectively). In contrast, 
cells of eggs inoculated with 60 µg/egg show slightly lower average, and much lower 
variability. Embryos inoculated with 20, 25, and 60 µg/egg did not show significant 
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differences (p>0.05) in the percentages of cells expressing HN protein. These results also 
show that small amounts of plasmid DNA (1 µg/egg) are able to transfect the embryo 
resulting in protein expression. The backbone plasmid results (1.95%) were considered 
background. We also observed a dose-dependent response inferring that higher amounts 






























Figure 8 – Percentages of splenocytes expressing HN from embryos inoculated at 18 
days of embryonation. Embyos were inoculated through the amniotic cavity with 1, 10, 
25, 60 and 100 µg/egg of pIRES-HN-EGFP DNA mixed with PEI ExGen®, whereas, the 
control group consisted of 60 µg/egg of pIRES-EGFP DNA. The spleens were collected 
prior to hatch and processed for flow cytometry analyses. Bars represent the standard 
deviation per group analyzed. No significant differences were observed among embryos 
inoculated with 10, 25 and 60 µg/egg of plasmid DNA.
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3.9. Serology
Tear samples were collected at 3 weeks and serum at 3 and 5 weeks post in ovo
vaccination. All samples were analyzed for IgA, IgG, and IgM immune responses. All 
samples were negative for all three immunoglobulins tested at 3 weeks post-vaccination. 
At 5 weeks of age, three serum samples were positive for IgM. Figure 9 shows the mean 
of each treatment group. 
At 5 weeks post-vaccination, two birds (2/6) that received the pIRES-HN-EGFP 
plasmid were considered positive as measured by commercial ELISA (data not shown). 
All tear and serum samples analysed by hemagglutination inhibition (HI) test were 












Figure 9 – IgM isotype-ELISA results from serum samples collected at 5 weeks post 
in ovo vaccination with 60 µg/egg of pIRES-HN-EGFP DNA. SPF, 18-day-old 
embryos were vaccinated through the amniotic cavity using PEI-ExGen®. Graph 
shows the mean of the ratios between sample and positive control. Negative control 
embryos were unvaccinated. Plasmid DNA control embryos were inoculated with pIRES-
EGFP plasmid DNA lacking the HN gene. 
DISCUSSION
Previous research has indicated in ovo DNA vaccines can be delivered into the air 
cell of ECE when encapsulated by neutral lipids such as IFA and DMSO (Oshop et al., 
2003). We obtained similar results regarding EGFP expression when using the air cell 
route. Hatchability rates of 52-57% were also similar. In addition, the air cell was 
compared with the amniotic cavity route, which is routinely used for Marek’s in ovo
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vaccination of chickens in the poultry industry. When the plasmid DNA was delivered by 
the amniotic cavity a significantly higher percentage of tissues expressed EGFP. 
Wakenell and co-workers evaluated the air cell route for delivery of Marek’s 
vaccine in ovo. The authors reported a lack of vaccinal response caused by the inability of 
the virus to cross the air cell membrane (Wakenell et al., 2002). On the other hand, Oshop 
and co-workers, suggest that DMSO may increase permeability through membranes, thus 
enhancing plasmid DNA up take by the embryo (Oshop et al., 2003).  Considering that 
plasmid DNA does not replicate as MDV and thus, its capacity to cross embryos 
membranes have to be mediated by a carrier such as DMSO. However, we obtained 
lower level of expression through the air cell. In addition, a dramatic decrease in 
hatchability of embryos vaccinated with IFA and DMSO formulation (52%) was 
observed when compared to ExGen® (97%). In our studies, embryos inoculated with 
DMSO that had died before hatch exhibited evidence of hepatic toxicity (data not 
shown). Affected livers were larger with severe congestion, and hemorrhages. The 
average hatchability rate in the poultry industry is 83%; lower rates represent a large loss 
in productivity. The results obtained in our studies using ExGen® as a vaccine adjuvant 
for in ovo inoculation were excellent. In addition, a consistent expression of the reporter 
gene in the muscle and lungs of embryos inoculated by either route or formulation was 
observed. For these reasons, it was decided to use the amniotic route and ExGen® to 
deliver plasmid DNA in the vaccine experiments. It is also important to point out that the 
cost of this cationic lipid (ExGen®) is very high to be considered for commercial 
applications.  
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High titers of IBDV in the lungs of embryos vaccinated by in ovo injection were 
reported, suggesting that this organ may play a main role in vaccine spread and protection 
(Sharma, 1986). In this previous experiment, muscle as well as lungs had the highest 
expression rates of the reporter gene, independent of route or formulation used (64 and 
40%, respectively).
Another important aspect of in ovo plasmid DNA delivery was addressed in 
Experiment 2. Five different dosages of plasmid DNA (1, 10, 25, 60, 100 µg/egg) were 
evaluated for protein expression. A prior report observed a dose-dependent response in 
18-day-old embryos and better responses were obtained using 60 µg/egg of plasmid DNA 
(Oshop et al, 2003). Flow cytometry results also showed a dose-dependent response to 
plasmid DNA using 1, 10, 25 and 60 µg/egg, but expression efficiency decreased with a 
dose of 100 µg/egg. The highest percentage of HN labelled cells was seen in the groups 
inoculated with 10 and 25 µg/egg (9.63% and 8.72%, respectively). However, these 
groups also had a high standard deviation that suggests inconsistent results. For this 
reason, we decided to use 60 µg of plasmid DNA/egg in future experiments because there 
were no significant differences among these three groups (10, 25 and 60 µg/egg). In 
addition, the 60 µg/egg group presented a much lower standard deviation (1.36). Similar 
results were observed by Oshop and co-workers when CAT protein expression was 
measured by AC-ELISA (Oshop et al., 2003). These studies also show that small 
amounts of plasmid DNA (1 µg/egg) are able to transfect the embryos resulting in protein 
expression (HN), and that large amounts of DNA may have a detrimental effect on 
transfection efficiency.
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The immune responses induced by in ovo inoculation of plasmid DNA pIRES-
HN-EGFP was measured by ELISA, isotype ELISA, and HI. A humoral response was 
not detected until 5 weeks of age. Few birds seroconverted as measured by commercial 
ELISA. Considerable IgM levels were detected by the isotype ELISA, indicating a 
primary immune response. All samples were negative for IgA suggesting that DNA 
vaccines delivered in ovo may not stimulate mucosal immunity.
Several important factors for in ovo DNA vaccine delivery were considered in this 
study. Using a well-studied promoter (CMV) (Oshop et al., 2003; Suarez, 2000; Kodihalli 
et al., 1997) two routes, two formulations, and five dosages for DNA vaccine delivery 
were evaluated. The humoral immune responses against plasmid DNA that encodes the 
HN gene from NDV were also evaluated. In the next study, these findings will be applied 
in the development of a DNA vaccine against IBDV.
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CHAPTER 4
DEVELOPMENT AND EVALUATION OF AN
IN OVO PLASMID DNA VACCINE AGAINST IBDV 
ABSTRACT
IBDV is a highly contagious disease of chickens, which is controlled by live and 
inactivated vaccines. In this study, we evaluated a novel approach to vaccinate chickens 
against IBDV using DNA vaccinology. Plasmid DNA was administered in ovo to 18-day-
old embryos. The DNA vaccine expresses the polyprotein VP2-VP4-VP3 of IBDV. The 
VP2 gene expresses epitopes of D78 strain and variant strain of GLS. VP3 and VP4 
genes are from D78. VP2-VP4-VP3 genes were inserted into a plasmid vector (pVAX1) 
and their expression verified by immunostaining assays. SPF and fertile broiler eggs with 
maternal antibodies were vaccinated and hatched chicks were challenged against IBDV-
STC. Each embryo received 60 µg of the DNA vaccine delivered into the amniotic 
cavity. In addition, a control group was inoculated with plasmid DNA without insert. 
Two groups of birds (SPF and broilers) received a booster immunization with baculovirus 
expressed-proteins of IBDV. The DNA vaccine had no detrimental effect on hatchability 
or first week post-hatch survival. In ovo vaccination generated detectable humoral 
immune responses as measured by ELISA. Antibody response was significantly 
enhanced two weeks after the birds received the IBDV-protein boost. However, no 
significant protection was observed in all vaccinated groups. BF had severe microscopic 
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lesions. Broilers vaccinated with plasmid DNA or IBDV-protein had partial protection 
possibly due to maternal antibodies. 
INTRODUCTION
Broiler breeders are immunized with live and inactivated vaccines in order to 
confer passive immunity to the progeny (van den Berg et al., 1991). Delivery of 
inactivated vaccines in breeders is time consuming, laborious, and inaccurate because 
each animal is inoculated intramuscularly or subcutaneously (Lukert and Saif, 1997) 
During the first few weeks of life, broiler chicks are protected against IBDV by 
maternally acquired passive immunity. However, passive immunity decreases rapidly as 
the chick ages, leaving it susceptible to IBDV infection. Thus, it is a routine practice in 
the poultry industry to vaccinate young chicks against IBDV to control the disease. The 
optimal age for live vaccination in broilers is difficult to predict (Lutticken et al., 1994). 
If the vaccine is administered too early, neutralization of maternal antibodies may occur. 
Vaccine administration later in life may leave the birds susceptible to the disease. In 
addition, live vaccines, when administered in ovo, may cause microscopic lesions in the 
BF because the immune system of the embryo is too immature to respond adequately to 
the vaccine (Giambrone et al., 2001; Sharma, 1986).
A more recent approach to vaccinate humans and animals against infectious 
agents was created after the discovery that a simple inoculation of naked plasmid DNA
could generate a humoral and cellular immune response (Tang, 1992). Since then, much 
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advancement in DNA vaccinology has been made. One important advantage of DNA 
vaccines is their possible use in neonatal animals. Apparently, passive maternal 
antibodies seem to have no interference with DNA vaccines (Babiuk, 1999; Siegrist, 
2001; Hasset et al., 2000). 
In order to circumvent the potential disadvantages of live and inactivated vaccines 
against IBDV and to evaluate the possibility of maternal antibody interference, we 
developed a plasmid DNA vaccine for SPF and broiler chicks. The specific objective of 
this study are: 1) evaluate the immunogenicity and protective efficacy of an in ovo IBDV 
vaccine in SPF chickens; 2) in broiler chicks with maternally acquired immunity; 3) 
examine the efficacy of a prime-boost strategy with IBDV DNA vaccine and baculovirus-
expressed subunit vaccine in SPF and broiler chicks.  
MATERIALS AND METHODS
4.1. Construction of a DNA vaccine expressing VP2-VP4-VP3 proteins of 
IBDV
A plasmid DNA that contains VP2 epitopes from variant strain GLS-IBDV 
(residues A, E, and S), and from standard strain D78 (P, Q, and G) was previously 
constructed. VP4 and VP3 genes were derived from standard strain D78-IBDV. In 
addition, the gene that encodes the nonstructural protein (NS) was ablated. This plasmid
was denoted pUC19B69GLSVP2∆NS (Liu, 2003). The insert pUC19B69GLSVP2∆NS 
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and pVAX1 vector were digested with EcoRI. In order to avoid re-ligation of pVAX1, 
treatment with alkaline phosphatase was performed. The 3.2 Kb fragment 
(B69GLSVP2∆NS) and pVAX1 were purified from a 1% agarose gel and ligated. The 
resulting DNA vaccine construct was designated pVAX1-B69GLSVP2∆NS. E.coli cells 
were transformed by the vaccine construct and plated. E.coli colonies were selected and 
plasmid DNA was purified. The correct orientation of the inserted gene was checked by 
BamHI digestion. The inserted genes were sequenced and analyzed for correctness. Large 
amount of endotoxin-free plasmid DNA were obtained from Aldevron (Fargo, ND). 
Plasmid concentration was determined by 260 nm spectrophotometer reading, and 
RNA/DNA contamination was checked by agarose gel. We decided to use pVAX1 as a 
vector because it was specifically designed for use in DNA vaccinology. It contains the 
CMV promoter, kanamycin resistance gene for selection in E. coli, and is only 3Kb in 
size. 
4.2. In vitro expression of pVAX1-B69GLSVP2∆NS  
Transient transfection of Vero cells was performed to verify protein expression by 
the vaccine construct. Vero cells were transfected and immunostained as described in 
section 3.2, except in this study Lipofectin was used as the transfection reagent instead of 
LipofectAmine. IBDV proteins were detected using a polyclonal chicken anti-IBDV 
(1:500) and goat anti-chicken IgG (H+L) peroxidase labeled (1:1000), and peroxidase 
substrate (Trueblue®). A rIBDVNS∆ mutant virus strain was used as positive control. 
The negative control consisted of cells not transfected by the plasmid DNA.
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4.3. Experimental design 
Commercial and SPF (Sunrise Farms, Catskill, NY) fertile eggs were incubated at 
100°F with 40-60% humidity. All SPF eggs used were from the same source. The 
commercial eggs were from a 36-week- old broiler breeders flock immunized against 
IBDV from a local company. The vaccination program for these breeders consisted of 
one live IBDV vaccination at 4 weeks of age, and booster vaccinations at 10 and 18 
weeks of age with an inactivated oil-emulsion vaccine containing standard and variant 
strains of IBDV. 
The plasmid pVAX1-IBDV (60 µg/egg) was mixed with 50 µl of 5% sterile 
glucose solution. Six equivalents of PEI (ExGen®500 in vivo transfection, MBI 
Fermentas) were diluted in 50 µl of 5% sterile glucose solution. ExGen® solution was 
added to the plasmid DNA, mixed, and incubated at RT for 15 min. In ovo inoculation, 
through the amniotic cavity at 18 days of embryonation, was performed as described in 
Section 3.2., Experiment 1. Treatment groups and number of eggs per group are shown in 
Table 1. A larger number of eggs were utilized for treatment groups A, B, C, and F 
because of the possibility of adverse effect due to vaccination. Sample size was 
calculated accordingly to protocol previously approved, and available isolators at BL2 
facility. After in ovo inoculation, all injection sites were sealed with adhesive tape. Eggs 
were replaced into the hatcher and incubated for three more days at 100 ºF with 60-80% 
humidity. 
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All hatched chicks were transferred to BL-2 isolators. Animal care and sample 
collections were performed as described earlier (Section 3.2., Experiment 3). One-week-
old birds from groups B and G received of 0.5 mL of IBDV protein lysate (6.8 mg/mL) 
subcutaneously as a secondary vaccine. At 3 weeks of age, all birds were bled and 
challenged. 
Seven days post-challenge, birds were then anesthetized with isoflurane, and 3-6 
mL of blood was collected by cardiac puncture. The birds were then humanely 
euthanized and spleens and BF were collected. Spleens and half of each BF were fixed in 
10% buffered formalin for seven days. After fixation, all tissues were stored in 70% 
alcohol and submitted to American Histolabs (Gaithersburg, MD) for HE staining. The 
other half of the BF collected at the necropsy was used for antigen-capture ELISA 
detection.
Table 1 – Treatment groups to evaluate plasmid DNA vaccine administered in ovo.
Group Egg type Treatment # of eggs 
A SPFa Plasmid DNA vaccineb 12
B Plasmid DNA vaccine + protein boostc 12
C Plasmid DNA controld 10
D NV/NCHe 8
E NV/CHf 8
F Broilersg Plasmid DNA vaccine 10
G Plasmid DNA vaccine + protein boost 9
H NV/NCH 9
I NV/CH 9
a - specific-pathogen-free eggs.
b - 18-day-old embryos received 0.2 mL of pVAX1-IBDV DNA vaccine (60 µg/egg).
c - one-week-old birds received 0.5 mL of protein boost expressed in baculovirus subcutaneously.
d - eggs inoculated with 60µg of pVAX1.
e - non-vaccinated, non-challenged control group.
f - non-vaccinated, challenged control group.
g - fertile broiler eggs from a local poultry farm.
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4.4. Expression and detection of baculovirus expressed-IBDV proteins 
Baculovirus expressing IBDV structural protein genes of GLS strain was a gift 
from Dr. Raghunath Shivappa. Recombinant virus vIBD-7 was obtained by 
cotransfecting pGLSBacI and Autographa california nuclear polyhedrosis virus (AcNPV) 
DNA into Spodoptera frugiperda (Sf9) cells, and plaque-purifying the recombinant virus. 
The recombinant virus was grown in large amounts in Sf9 cells. 
4.5. Production and detection of baculovirus expressed-proteins of IBDV
Baculovirus expressed-proteins of IBDV used to boost one-week-old chicks were 
produced and harvested from Sf9 cells infected with baculovirus vIBD-7, as described 
(Vakharia et al., 1993). Briefly, infected cells were cultured in Grace's insect medium 
with 1% L-glutamine supplemented with 10% of FBS in 1L spinner flasks at 28ºC. After 
showing typical cytopathic effect (CPE) the Sf9 cells were centrifuged at 4,000 xg for 5 
min at 4°C.  The cell pellet was washed with cold PBS (pH 6.5) and sonicated for three 
times 15 sec each, cycle number 5 (Fisher Scientific Sonic Dismembrator, Model 100). 
Cell lysis was verified by trypan blue exclusion method. Aliquots were collected for 
western blotting and protein concentration assays. Total protein concentration (6.8 
mg/mL) was determined by BCA protein assay (Pierce, Rockford, IL). Clarified lysate 
was stored at –20ºC for further subcutaneous inoculation into chickens as a booster for 
primary DNA vaccination. 
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Detection of baculovirus protein expressed by the vIBD-7 construct was 
determined by Western blotting. Fifteen microliters of the cell lysate was mixed with 2X 
loading buffer (15 µl), boiled, and run on a 12.5% SDS-PAGE. The proteins were 
transferred from the gel by blotting onto nitrocellulose membrane and the membrane was 
blocked overnight in 2% non-fat dried milk solution. The membrane was incubated for 1 
h with rabbit-anti IBDV polyclonal antibodies (1:400). The membrane was washed and a 
secondary antibody, goat anti-rabbit phosphatase (Kirkegaard & Perry Laboratories) was 
added (1:1000) and incubated for 1 h, and washed. All washes were made three times, 
five min each with tris-buffered-saline (TBS) with 0.1% Triton-100X, and one final wash 
with TBS only. Finally, the protein was detected by naphthol phosphate fast red (Sigma).
4.6. IBDV challenge 
The challenge strain was titered using the mean embryo infectious dose (EID50) 
method since this strain does not grow in tissue culture. Serial dilutions of the IBDV-STC 
stocks were made and then 100 µl of each dilution was inoculated onto the 
chorioallantoic membrane (CAM) of 11-day-old ECE. The inoculated eggs were 
examined by candling for 6 days. IBDV causes embryo mortality from 3-5 days post-
inoculation. After seven days, the remaining embryos were chilled for 2 h and examined 
for IBDV specific lesions such as edematous distention of the abdominal region, 
cutaneous congestion and petechial hemorrhages, cerebral hemorrages, liver necrosis and 
hemorrhages, heart and lung congestion, mottled necrosis of kidneys, and small necrotic 
foci in the spleen. The CAM does not present plaques but may exhibit small hemorraghic 
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areas (Lukert and Saif, 1997). Then an EID50 was determined using the Reed-Muench 
formula. Aliquots of virus stock were stored at –20ºC.  
Each bird received 0.2 mL of 103 EID50 of IBDV standard challenge strain STC 
by oculo-nasal route. The birds were observed for clinical signs of IBDV. They were 
scored on a scale of 1 to 8 (Table 2). Birds that had a total score of 6 or higher from the 
viral challenge were anesthetized and humanely euthanized. The experiment was 
terminated on day 7 after viral challenge.
Table 2 - Scoring system to quantify pain, distress, and suffering after IBDV challenge.
A - Physical appearance/unprovoked behavior post-challengea Scoreb
Normal 0
Ruffled feathers; 1
Lack of grooming, reduced mobility; 2
Anorexia, inactive, trembling; 3
Violet comb, nasal and/or ocular discharge, whitish or watery diarrhea 4
B - Behavioral responses to external stimuli post-challenge Score
Normal 0




a - birds were challenged by ocular/nasal route. Each bird received 0.2 mL of 103 EID50 of IBDV 
standard challenge strain STC.  They were observed for clinical signs of IBDV three times a day. 
b - each bird was scored on a scale of 1 to 8. Birds that had a total score of 6 or higher from the viral 
challenge were anesthetized and humanely euthanized. The experiment was terminated on day 7 after 
viral challenge.
4.7. Assessing protection
Vaccine efficacy was determined by bursa/body weight ratios, survival to IBDV 
challenge, histopathological scoring, detection of viral antigen by AC-ELISA, and 
humoral immune responses. The bursa/body weight ratio was calculated as bursa 
- 83 -
weight/body weight x 1000. The vaccinated group was considered protected if all 
bursa/body weight ratios were equal or higher than 2SD (standard deviation) of the non-
vaccinated, non-challenged control group, indicating absence of bursal atrophy. 
To detect the presence of IBDV antigens and assess protection against challenge, 
a commercial antigen-capture ELISA kit (AC-ELISA) was used. The bursae were 
homogenized individually according to manufacturer’s recommendation and analysed 
using a panel of strain-specific IBDV monoclonal antibodies (Synbiotics, San Diego, 
CA).
Protection from IBDV challenge was also determined by evaluating the degree of 
microscopic bursal damage. BF sections from surviving birds were randomly read and 
scored using the scoring system shown in Table 3.  
Table 3 – Histological scoring system for bursal damage after infection with IBDV.
Damage scorea Histological features
0 No bursal damage in any follicle, clear demarcation of medulla and 
cortex
1 Mild necrosis of occasional follicles with overall bursal 
architecture maintained
2 < 50% of follicles with severe lymphocyte depletion
3 > 50% of follicles with severe lymphocyte depletion
4 Follicular outlines only remaining, increased connective tissue, 
cysts
5 Loss of all follicular architecture, fibroplasia
a - adapted from Muskett et al., 1979.
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4.8. Serology
Commercial ELISA kits (Synbiotics, San Diego, CA) were used to verify immune 
responses generated by pVAX1-IBDV DNA vaccine. This kit consists of plates coated 
with bursal derived IBDV antigen.
4.9. Statistical analysis
Data obtained from ELISA were statistically analyzed using the Student t-test 
(Statistix, version 7.0). Experimental group means were considered significantly different 
from each other if p<0.05. 
RESULTS
4.10. Cell transfection by pVAX1-VP2- VP4-VP3 plasmid DNA
The complete segment A encoding the polyprotein VP2-VP4-VP3 of IBDV was 
cloned in to the pVAX1 plasmid vector, as described in Section 4.2. The insert was 
sequenced to its entirely to confirm identity. In order to confirm that the construct 
expressed the VP2-VP4-VP3 polyprotein, Vero cells were transiently transfected and 
tested by immunostaining assay for protein expression. Our in vitro transfection 
experiments demonstrated the expression of VP2-VP4-VP3 (Figure 10).
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Figure 10 – In vitro expression of IBDV proteins in Vero cells after transfection with 
pVAX1-VP2- VP4-VP3 plasmid DNA. Vero cells were transfected with 5 µg of plasmid 
using Lipofectin and immunostained 48 h post-transfection. Cells were treated with 
polyclonal chicken anti-IBDV, labeled with goat anti-chicken peroxidase, and stained 
with Trueblue® Kirkegaard & Perry Lab., Gaithersburg, MD). A) mock-transfected cells 
(negative control); B) cells infected with rIBDV∆NS (positive control); C) cells 
transfected with pVAX1-IBDV plasmid DNA (Magnification 100X).
4.11. Detection of IBDV proteins 
In order to determine the expression of VP2, VP4, and VP3 in the baculovirus 
(vIBD-7) system, the Sf9 cell lysate was analyzed by Western blotting, which gave 
strong bands indicating IBDV protein expression (Figure 11, lane 4).
A B C
- 86 -
Figure 11 - Western blot results of vIBD-7 proteins expressed in Sf9 infected cells. Sf9 
cells were infected with a recombinant baculovirus (vIBD-7) expressing VP2-VP3-VP4 
polyprotein of IBDV. Cells were harvested 3 days post-inoculation. The samples were 
separated by SDS-PAGE on a 12.5% slab gel, blotted onto nitrocellulose, reacted with 
polyvalent rabbit anti-IBDV serum, and detected with goat anti-rabbit phosphatase 
labeled and developed by naphthol phosphate fast red. Lane 1, D78; Lane 2, GLS; Lane 
3, Marker; Lane 4, vIBD-7; Lane 5, un-infected Sf9 cells. 
4.12. Hatchability and first week survival rates post in ovo plasmid DNA 
vaccination
The hatchability and first week survival rates are shown in Table 4. The 
hatchability percentages from commercial broiler eggs were 70% to 100%. Commercial 
broiler eggs hatched significantly better than SPF embryos. The plasmid DNA vaccine 






may not have been responsible for this low hatchability, since non-vaccinated SPF 
embryos also had lower hatchability (50%). It is possible that the quality of SPF embryos 
shipped by our provider was poor.  
First week survival rates were 100% in broiler chicks. Survival at first week was 
compromised in the SPF groups. Hatched chicks in the SPF groups were weak and small, 
independently of treatment group, again reinforcing the view that egg quality at the time 
of receipt must have been poor.
Table 4 – Effect of in ovo vaccination of IBDV-DNA vaccine on hatchability and 
survival rates. 
Group Egg type Chicks hatched (%) 1st week survival (%)
A SPFa 11/12b (92) 10 (91)
B 10/12 (83) 10 (100)
C 4/10 (40) 4 (100)
D 4/8 (50) 3 (75)
E 4/8 (50) 3 (75)
F Broilersc 7/10 (70) 7 (100)
G 9/9 (100) 9 (100)
H 9/9 (100) 9 (100)
I 9/9 (100) 9 (100)
a - specific-pathogen-free eggs.
b - number of eggs vaccinated/ number of hatched chicks.
c - fertile broiler eggs from a poultry farm.
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4.13. Assessing protection
Table 5 summarizes results from plasmid DNA vaccine efficacy 7 days post 
IBDV challenge. SPF embryos vaccinated in ovo with plasmid DNA (group A) or boost 
at one-week of age (group B) were not protected against challenge. All vaccinated birds 
exhibited clinical signs of IBD three days after challenge. Two birds from group B died 7 
days post-challenge. Non-vaccinated, challenged control groups (E, and I) became 
severely ill and were humanely euthanized 3 days after challenge. The severity of clinical 
signs and mortality rate of group I (broilers) was significantly lower than group E (SPF). 
No protection was observed in birds from group C that was inoculated with control 
plasmid DNA. Broilers from group F were not protected either. Broiler embryos that 
received a boost  (group G) were partially protected. In this group, birds did not die after 
challenge, had the body/bursa weight ratios normal, and no viral antigen was detected by 
AC-ELISA. However, their BF showed a score of 3.67 in the histopathological 
examination, indicating severe bursal damage, and 50% of vaccinated birds (3/6) 
exhibited clinical signs of IBD.
IBDV-specific antigens in the BF were assessed by AC-ELISA and the results are 
summarized in Table 5. Viral antigen could not be detected by AC-ELISA in the bursae 
of SPF and broiler non-vaccinated, non-challenged control birds (D, H). Antigen was 
detected in 100% of samples from non-vaccinated, challenged control group and 66.7% 
in broilers (groups E, and I). All BFs from plasmid control (group C) had antigen 
detected at 7 days post-challenge. Three out of seven vaccinated SPF birds had IBDV 
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antigens detected by AC-ELISA. No antigen was detected in BF of SPF birds that 
received plasmid DNA and IBDV-protein boost (group B) Antigen was detected in 
vaccinated, challenged broilers group F (3/6). No viral antigen was detected in broiler 
birds from group G that received a protein boost at 7 days post-challenge.
Table 5 – Protection rate, bursa/body weight ratio, antigen detection, and 
histopathological scores from birds vaccinated in ovo with pVAX1-IBDV DNA at 7 days 
post IBDV-STC challenge.






A SPF 9/10e 2.18 ± 0.3f 3/7 4.62
B 7/10 2.08 ± 0.3 0/6 4.66
C 4/4 4.90 ± 1.7 3/3g 5.0
D NAh 7.11 ± 1.4 0/3 0
E NA 3.63 ± 0.3 3/3 4.6
F Broilers 5/6 1.96 ± 0.9 3/6 2.0
G 3/6 1.90 ± 0.8 0/6 3.67
H NA 1.48 ± 0.6 0/6 0
I NA 2.31 ± 0.5 4/6 4.6
a – number of birds exhibiting clinical signs of IBD post-challenge with 0.2 mL of 103EID50 of IBDV-
STC challenge.
b - (bursa weight/body weight) x 1000.
c - viral antigen detected by antigen capture ELISA.
d - mean of lesion scores. 
e - number of birds that died after challenge/number of birds challenged
f - mean of bursa/body weight and standard deviation.
g – number of birds positive for antigen detection as measured by AC-ELISA.
h – not applicable
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4.14. Histopathology
Table 5 shows the average of score lesions from microscopic analysis of BF from 
SPF and broiler chickens at 7 days post-challenge. No microscopic lesions were observed 
in chickens that were not vaccinated or challenged. In contrast, bursae from non-
vaccinated challenged SPF control birds showed lesion score 5.0 and severe lymphocytic 
necrosis, follicular cell depletion, extensive accumulation of inflammatory cells, and inter 
and intra-follicular cystic formation. A significant increase of connective tissue was 
observed, which resulted in the loss of distinction between the cortex and medulla. All 
vaccinated, and challenged SPF birds had high lesion scores (4.62 and 4.66) and 
exhibited severe microscopic lesions in the BF at 7 days post-challenge.
Non-vaccinated, challenged control broilers showed bursal lesions. However, they 
were not as severe as SPF challenged controls. In vaccinated broilers, lesions in the BF as 
well as spleen were dramatically different from bird to bird. In addition, broilers that 
received plasmid DNA vaccine presented mild to severe lymphocytic depletion. Embryos 
vaccinated with plasmid DNA and boosted with baculovirus expressed-IBDV protein had 
lesion score 2.0 and a high variability in the lesions caused by IBDV challenge.
The spleen was also microscopically analyzed (data not shown). SPF non-
vaccinated, challenged birds showed increased numbers of germinal centers when 
compared to non-challenged control group. The spleen was hemorrhagic and showed 
infiltration of inflammatory cells as well as white zones characteristic of cell depletion. 
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Non-vaccinated broilers that were challenged also showed lymphocytic depletion, but 
more generalized throughout the entire organ. Vaccinated SPF birds exhibited lesions in 
the spleens similar to the challenged control group. Milder lesions were observed in 
groups F and G.
4.15. Serology
Serological results from ELISA test are shown in Figure 12. The S/P ratios were 
calculated for each sample. As expected, all SPF non-vaccinated birds did not show 
antibody titers after three weeks of vaccination. The maternal antibody detected at three 
weeks of age in non-vaccinated commercial broilers was not uniform (mean= 1.89; 
SD=0.95). 
At three weeks post-vaccination 3/10 SPF birds vaccinated with plasmid DNA 
showed antibody responses as measured by ELISA. In addition, SPF birds vaccinated 
with plasmid DNA and boosted one week later were positive (S/P ratio=1.23). Group F 
showed ratios of 1.75, and broilers boosted with IBDV protein showed 1.58. 
At seven days post-challenge, a significant increase of humoral response was 
observed in SPF birds that received the plasmid DNA vaccine (groups A, and B). Birds 
inoculated with the control plasmid DNA remained negative. Commercial broilers 
vaccinated with plasmid DNA and protein boost had significantly increased (p<0.05) 
antibody responses (1.58 vs 1.90). However, commercial broilers that received plasmid 
vaccine only did not show an antibody increase 7 days after challenge, as measured by 
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ELISA. Antibody responses were not detected in SPF non-vaccinated, challenged birds 
after 7 days of challenge. Non-vaccinated, not challenged control group demonstrated a 














Figure 12 – ELISA results from birds vaccinated with pVAX1-IBDV DNA vaccine 
three weeks post in ovo vaccination and seven days post IBDV-STC challenge. A) 
SPF embryos vaccinated with plasmid DNA; B) SPF embryos vaccinated with plasmid 
DNA and boosted at one week of age with baculovirus expressed-IBDV proteins; C) SPF 
embryos vaccinated with plasmid DNA control (pVAX1); D) SPF unvaccinated, non-
challenged control group; E) SPF unvaccinated; challenged at 3 weeks post plasmid DNA 
vaccination; F) broiler embryos vaccinated with plasmid DNA; G) broiler embryos 
vaccinated with plasmid DNA and boosted at one week of age with baculovirus 
expressed-IBDV proteins; H) broiler embryos unvaccinated and non-challenged; I) 
broiler embryos non-vaccinated, and challenged.
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DISCUSSION
IBDV remains a serious problem for commercial broiler producers. Chickens 
vaccinated with IBD vaccines are not protected against variant or vvIBDV strains. In 
addition, immunity conferred by live vaccines induced mild to moderate bursal atrophy 
(Tsukamoto et al., 1995).  Previous work has indicated that in ovo vaccination against 
IBDV using live intermediate vaccines, can lead to disease and immunosuppression due 
to microscopic lesions in the BF (Lukert and Saif, 1997). In addition, these viruses may 
be able to revert to a virulent state. 
Therefore, a safer and more efficacious vaccine to control IBD is necessary. 
Plasmid DNA vaccination has been used in recent years as a new way to induce host 
immune responses. Few studies reported the use of a plasmid DNA vaccine against 
IBDV. Plasmid DNA vaccine expressing the polyprotein VP2-VP4-VP3 induced specific 
antibodies and partially protected chickens immunized intramuscularly and 
intraperitonealy (Chang et al., 2001; Fodor et al., 1999). In this study, we demonstrated 
that a plasmid DNA vaccine expressing the polyprotein (VP2-VP4-VP3) of IBDV 
conferred partial protection against IBDV challenge in commercial broilers when 
delivered to 18-day-old embryos. On the other hand, SPF embryos that lack maternal 
antibodies did not show protection against challenge.
These results were obtained using an expression vector under the control of the 
CMV promoter containing IBDV genes for VP2-VP3-VP4 polyprotein followed by in 
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ovo inoculation of 18-day-old embryos. In order to enhance the immune responses 
generated by plasmid DNA vaccination, SPF and broilers were boosted subcutaneously 
with a subunit vaccine generated in the baculovirus system at one week post-hatch. Our 
study showed that this secondary vaccination induced a higher level of antibody 
responses in SPF birds. Antibody responses measured by ELISA two weeks after boost 
were significantly higher when compared to birds that were vaccinated with plasmid 
DNA only (S/P ratio = 1.3 vs 0.3).  Partial protection was observed in commercial eggs 
inoculated with plasmid DNA vaccine and boosted one week of age. Previous studies 
using the same baculovirus construct obtained protection when two-week-old leghorns 
were inoculated intramuscularly, boosted 4 weeks later and challenged with IBDV-GLS 
strain (Vakharia et al., 1993). In another study using the same construct but with 
antigenic mass 4-fold its original resulted in full protection against STC, E/Del, and GLS 
challenges (Vakharia et al., 1994). It is possible to infer from these results, that better 
protection could have been provided if boost was performed with higher concentrations 
of the IBDV-protein later in life. However, the lifetime of a broiler chick is 48-49 days 
and several inoculations for vaccine boost are not practical.
We also demonstrated that bursal damage and lesions after challenge in non-
vaccinated control broilers were highly variable from bird to bird. These findings suggest 
that the level of protection observed is not exclusively due to the DNA vaccine but as 
well as to maternal antibodies. As measured by ELISA, maternal antibody titers were not 
uniform (ranging from 345 to 5455). Also, passive immunity waned significantly after 3 
weeks of age to sub-protective levels, indicating that the vaccination program used in the 
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breeder flock was not adequate to protect young chicks from IBDV challenges in the field 
during the first few weeks of life.
In this study, we could not demonstrate that DNA vaccines may be able to 
overcome maternal immunity since broilers that received plasmid vaccine did not show 
an antibody increase three weeks post in ovo vaccination, as measured by ELISA. In 
addition, only a few SPF birds seroconverted. Low levels of antibody responses after 
plasmid DNA vaccination have been reported by other investigators (Heckert et al., 2002; 
Kodihalli et al., 2000; Chang et al., 2001; Kodihalli et al., 1997). Our findings also 
suggest that cellular immunity may have played a role in partially protecting vaccinated 
broilers. Other authors obtained similar results, indicating that protection may due to the 
presence of CTL rather then antibody immune response (Oshop et al., 2003; Wang et al, 
2003; Seo et al., 1997).
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CHAPTER 5
RECOMBINANT ATTENUATED IBDV VACCINE DELIVERED IN OVO
CONFERS PROTECTION IN CHICKENS
ABSTRACT
A recombinant attenuated vaccine against IBDV was administered in ovo to 18-
day-old embryos. The vaccine was genetically tailored to protect from challenges in the 
field against classic and variant strains of IBDV. The vaccine virus contains neutralizing 
epitopes from both classic (D78) and variant strain (GLS), and abrogates expression of 
the nonstructural protein, VP5 of IBDV. SPF and fertile broiler eggs obtained from a 
local poultry farm were vaccinated and used to evaluate protection against IBDV-STC 
challenge. A full dose of the vaccine consisting of 5.6x103 pfu was administered to SPF 
and broiler embryos. In addition, a half dose of the vaccine containing 2.3x103 pfu was 
injected into SPF embryos. The vaccine had no effect on hatchability or first week 
survival in either broilers or SPF birds, even when high doses were administered. The 
vaccine generated high antibody titers in chickens with either dosage. All vaccinated 
groups were protected against mortality. The vaccine did not cause bursal damage and 
fully protected SPF chickens vaccinated in ovo with half dose of the vaccine and broiler 
chicks that received a full dose of the recombinant vaccine in ovo. 
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INTRODUCTION
IBD is an acute, contagious disease caused by a double-stranded RNA virus of the 
Birnaviridae family, IBDV. IBDV genome consists of two segments, A and B. The larger 
segment A contains two overlapping ORF that encodes a polyprotein VP2-VP4-VP3 and 
a nonstructural protein, VP5. Segment B codes for a 97 Kda protein, designated VP1, 
which represents the viral RNA-dependent RNA polymerase. The virus targets the 
lymphoid tissue of chickens mainly the BF, causing severe bursal damage, and 
consequently immunosuppression. Thus, IBD is of major economic importance to the 
poultry industry.  
A strategy for the control of IBD in chicks involves hyperimmunization of 
breeders, which allows them to transmit high levels of maternal antibodies to progeny 
during the critical first few weeks of life. Although maternal antibodies provide 
protection during this period, continued protection against IBDV must be maintained 
before the maternal immunity reaches sub-protective levels by the administration of live 
vaccines. However, maternal antibodies can neutralize vaccine virus and reduce the viral 
load needed to induce immunity (Sharma et al., 1987). In addition, new antigenic variants 
of IBDV, which appeared during the 1980’s, introduced new problems for poultry 
production. These new field isolates were able to break through neutralizing maternal 
antibodies induced by standard IBDV vaccines (Snyder, 1992). Since then, these variant 
strains have been incorporated into commercial inactivated vaccines for broiler breeders. 
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Unfortunately, despite these vaccination measures, IBDV continues to be a problem. 
Very virulent strains of IBDV have caused outbreaks of disease with high mortality in 
Europe and Asia (Nunoya et al., 1992; van den Berg et al., 1991) despite vaccination 
programs. In addition, live vaccines that are available for mass vaccination of broilers in 
the first few weeks of life are not suitable for in ovo administration. These vaccines may 
induce immunosuppression during late stages of incubation, when the embryo is highly 
susceptible to infection. 
Therefore, in an effort to aid in the control of this disease, a recombinant IBD 
vaccine virus that can protect against both classical and variant strains was created in our 
laboratory, using reverse genetics system (Liu, 2003). This virus, designated as 
rD78GLSNS∆, is deficient in the expression of VP5 nonstructural protein (NS). It grows 
one log lower than the parental viruses, and exhibits decreased cytotoxic and apoptotic 
effects in cell culture. This virus fails to induce any pathological lesions in the bursa of 
infected three-week- old chickens. In addition, vaccinated birds challenged with classic 
(STC) and variant (GLS) strains of IBDV were fully protected.
In this report, we evaluate the potential use of this recombinant attenuated virus in 
ovo to protect SPF as well as commercial chicks from IBDV challenges. Fertile eggs 
were obtained from a local poultry farm that routinely immunizes broiler breeders with 
live and inactivated vaccines to confer high levels of maternal antibodies to the progeny. 
The vaccination program for these breeders consisted of one live IBDV vaccination at 4 
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weeks of age, and booster vaccinations at 10 and 18 weeks of age with an inactivated oil-
emulsion vaccine containing standard and variant strains of IBDV. 
Two different doses of this recombinant vaccine were evaluated in SPF eggs in 
the absence of maternal antibodies. A full dose was used to vaccinate broiler embryos 
with maternal antibodies to verify its ability to break through antibody barrier and 
generate a protective immune response against IBDV challenges.
MATERIALS AND METHODS
5.1. Cells and viruses
Vero cells were maintained in medium 199 (M199) supplemented with 5% FBS at 
37°C in a humidified 5% CO2 incubator and used for propagation of the virus. Primary 
chicken embryo fibroblast (CEF) cells were prepared as described previously (Mundt and 
Vakharia, 1996). Briefly, ten-day-old embryos from SPF chickens were aseptically 
removed and cut into pieces. The tissues were rinsed in HBSS and digested with 0.2% 
trypsin at 37°C for one h to produce a single cell suspension. The suspension was filtered 
through gauze and washed twice with HBSS. The cells were grown in M199 and F10 (1:1 
v/v) with 10% FBS. Secondary CEF cells, used for virus titration, were maintained in 
growth medium consisting of M199 and F10 with 5% FBS. 
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5.2. Propagation and purification of IBDV
The recombinant IBD vaccine virus, rD78GLSNS∆, was prepared as described 
(Liu, 2003). Large amounts of this virus were grown in Vero cells as stock for in ovo
inoculations, and stored at –20 °C.
5.3. Plaque assays
Virus stocks propagated in cell culture were titered by plaque assay as described 
earlier (Mundt and Vakharia, 1996). Briefly, the infected supernatant was diluted in ten-
fold increments in MEM without FCS. Confluent monolayers of CEFs were infected with 
serial dilutions of viruses (10-4 to 10-7, 0.1 mL/well). After 1 h adsorption at RT, the 
media was removed and the monolayer overlaid with 3 mL of 1% SeaPlaque agarose 
(Difco) containing 10% tryptose phosphate broth, 2% FCS, 0.112% NaHCO3, 100 
unit/mL penicillin, 100 µg/mL streptomycin and 0.25 µg/mL fungizone. On day 3, the 
agarose overlay was removed and cells were fixed with formalin. After fixing, the cells 
were stained with crystal violet and plaques were counted and expressed as plaque 
forming units (pfu/mL).
5.4. Experimental design 
The experimental groups and controls are shown in Table 6. A larger number of 
eggs were utilized for treatment groups A, B, and E (vaccinated) because of a possible 
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adverse effect due to vaccination. Sample size was calculated accordingly to protocol 
previously approved. SPF and commercial fertile broiler eggs of 18 days of embryonation 
were inoculated in a manner similar to that previously described in Chapter 3, using a full 
dose of rIBDV (group A, and E). Each embryo received 5.6x103 pfu/0.2 mL of 
rD78GLSNS∆. Another group of SPF eggs received only half a dose of this virus, which 
was 2.3x103 pfu/0.2 mL (group B). The negative controls consisted of non-vaccinated, 
unchallenged SPF and commercial embryos (groups D, and G). The challenge control 
groups consisted of SPF and commercial eggs, which did not receive the vaccine and 
were challenged two weeks post-vaccination (groups C, and F). After in ovo vaccination, 
all eggs were sealed with adhesive tape and re-incubated.
Table 6 – Experimental design to evaluate live attenuated rIBDV vaccine.
a - 18-day-old embryos received 0.2 mL of rIBDV vaccine containing either 5.6x103 or 2.3x103 pfu.
b - specific-pathogen-free fertile eggs.
c - non-vaccinated, challenged control group.
d - non-vaccinated, non-challenged control group.
e - fertile broiler eggs from a poultry farm.
Group Egg type Vaccine dosea (pfu) # of eggs
A SPFb 5.6 x 103 27
B 2.3 x 103 27
C NV/CHc 17
D NV/NCHd 17




The SPF embryos were free of any other immunosuppressive diseases that could 
compromise our results, such as adenoviruses, and chicken anaemia virus. The 
commercial eggs were obtained from the same poultry company as described in section 
4.3. 
After 21 days of incubation, all hatched chicks were housed in BL-2 isolators and 
cared for under the same conditions described in Chapter 3. Two weeks post-hatch, all 
birds were bled and challenged with STC strain (0.2 mL by the ocular and nasal route -
103 EID50) of IBDV, except group D, and G. At ten days post-challenge, all the 
remaining birds were anesthetized, bled, and humanely euthanized. Spleen and bursa 
were collected and bursa/body weight recorded. The bursae were sectioned in half. 
Spleen and bursa halves were placed in 10% buffered formalin for histology. The other 
half of the bursa was stored frozen for later testing by AC-ELISA.
The antibody levels in serum samples collected at 2 weeks post-vaccination, and 
10 days post-challenge, were determined by ELISA and VN. A commercial ELISA kit 
was used (Synbiotics, San Diego, CA). The frozen bursae were processed as described 
earlier and probed for antigen detection by AC-ELISA (Synbiotics, San Diego, CA). 
Fixed tissues were sectioned at American Histolabs (Gaithersburg, MD) and stained by 
hematoxylin-eosin (HE). We used the same criteria to determine protection against IBDV 
challenge as described in Chapter 4. 
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5.5. Virus neutralization assay (VN)
Serum samples were heat-inactivated at 56°C for 1 h and diluted in serial two-fold 
dilutions. Each dilution was mixed with 100 TCID50 of rIBDV and incubated for 1 h at 
37°C. The mixture was added to 85-90% confluent monolayer of Vero cells, grown in 
96-well tissue culture plates (Costar, Ithaca, NY). All plates were incubated for 5-6 days 
until the presence of CPE was detected in the virus control wells. Normal serum from 
SPF birds was used as a negative control and a polyclonal anti-IBDV (SPAFAS) was 
used as a positive control. Anti-IBDV titers were determined 5-6 days later, averaged, 
and expressed as Log2.
RESULTS
5.6. Vaccine safety
Hatchability and first week survival rates are shown in Table 7. The hatchability 
rates in SPF eggs from group A and B were similar (92.5%), indicating that the vaccine is 
safe even when higher doses were administered. The percentages of hatched birds and 
first week survival were not significantly different from vaccinated groups and control
non-vaccinated. The hatchability rates in broilers were lower than SPF embryos. 
However, we do not believe the vaccine caused these changes, since non-vaccinated birds 
also exhibited lower hatchability (88.8%). We attributed it to stress caused by 
temperature shock during transportation. Embryonated eggs were removed from 
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incubators at 37ºC and transported at 22ºC for 2 h. The hatchability in this experiment is 
much higher than the average observed in the poultry industry (83%) because all unviable 
eggs were discarded prior to in ovo vaccination. 
Table 7 – Effect of in ovo vaccination of rIBDV on hatchability and survival of hatched 
chicks.
Group Egg type # of chicks hatched (%) 1st week survival rate (%)
A SPF 25/27 (92.5) a 24 (96)
B 25/27 (92.5) 25 (100)
C 16/17 (94.1) 16 (100)
D 17/17 (100) 17 (100)
E Broilers 18/24 (75) 17 (94.4)
F 7/9 (77.8) 7 (100)
G 8/9 (88.8) 8 (100)
a – percentage of hatched chicks after in ovo vaccination with rIBDV.
5.7. Vaccine protection
Results of the IBDV challenge studies are shown in Table 8. All vaccinated birds 
were fully protected against IBDV-STC. The bursa/body weight ratio was calculated as 
bursa weight/body weight x 1000. The vaccinated group was considered protected if all 
bursa/body weight ratios were equal or higher than 2SD (standard deviation) of the non-
vaccinated, non-challenged control group. The mean for the SPF control (group D) was 
5.35 (2SD=2.48). Thus, all SPF vaccinated birds with either dose were considered 
protected. Additionally, vaccinated broilers were also considered fully protected.
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Table 8 also shows results from antigen detection assessed by AC-ELISA 
(Synbiotics, San Diego, CA) seven days post-challenge. IBDV antigen was detected in 
two SPF birds that were vaccinated with full dose of the vaccine. Viral antigens could not 
be detected in the BF of birds that received half dose of the vaccine or in broilers that 
received full dose. Antigen was detected in SPF challenge control group (11/12). As 
expected, no IBDV antigen could be detected in the negative control birds (group D, and 
G), whereas non-vaccinated, challenged broilers (8/9) were positive by AC-ELISA at 10 
days post-challenge. 
Table 8 – Protection indices from birds vaccinated with rIBDV-attenuated vaccine and 
challenged with the classic STC strain of IBDV.




VN Log2d Lesion 
Score
A 0/20e  (100)f 6.04  ±  1.2g 2/12 8.76 7.90 2.0
B 0/18  (100) 5.27  ±  1.5 0/11 9.25 5.47 0
C 12/12 (NA)h 4.31  ±  1.1 11/12 4.00 2.33 5.0
D 0/12  (NA) 5.35  ±  1.2 0/12 3.16 4.00 0
E 0/17  (100) 2.14  ±  0.8 0/11 9.46 7.58 0
F 10/12  (NA) 1.48  ±  0.6 8/9 5.3 6.8 4.6
G 0/12  (NA) 2.31  ±  0.5 0/9 5.4 6.8 0
a - at two weeks post-vaccination birds received 0.2 mL of 103EID50% of IBDV-STC challenge.
b - (bursa weight/body weight) x 1000.
c - number of birds that had antigen detected as measured by antigen capture ELISA.
d - virus neutralization results two weeks post-vaccination and ten days post-challenge. 
e - number of birds dead/ number of birds challenged.
f - percentage of protected birds.
g -  mean of bursa/body weight rations and standard deviation. 
h - not applicable. 
- 106 -
5.8. Antibody responses 
The antibody responses as measured by commercial ELISA are shown in Figure 
13. At two weeks post-vaccination, all vaccinated groups had significantly higher 
antibody titers (p<0.05) than non-vaccinated groups by either test. As expected, all non-
vaccinated SPF birds had negative titers for IBDV at 2 weeks post-vaccination. The non-
vaccinated, commercial broilers had maternal antibody titers ranging from 455 to 5455 at 
2 weeks of age. At 10 days post-challenge, all SPF vaccinated groups (full and half dose) 
showed significantly (p<0.05) higher titers than the same groups at two weeks post-
vaccination. However, broilers receiving a full vaccine dose did not show an antibody 
increase after challenge as measured by ELISA. Antibody responses at 2 weeks post-
vaccination in SPF birds that received half dose of the vaccine were relatively higher than 
SPF birds vaccinated with a full dose. The level of protective maternal antibodies in the 
non-vaccinated, unchallenged broilers seemed to wane slightly after challenge. Antibody 
responses were not detected in SPF non-vaccinated, challenged control birds after 10 
days of challenge. This result is expected considering that a primary immune response 
would take at least 2 weeks to be detected.
The results from virus neutralization assay are expressed as log2 in Table 8. All 
vaccinated groups showed protective levels (between 4-6 log2) of antibodies 2 weeks 
post-vaccination. Non-vaccinated control broilers showed maternal antibody levels (4.8 
log2) lower than normal for the first few weeks of life. All control groups continued to 
exhibit only low levels of antibodies 10 days post-challenge. As expected, all vaccinated 
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SPF birds showed higher humoral responses after challenge. Contradicting ELISA 
results, vaccinated broilers also showed higher antibody response 10 days post-challenge 













Figure 13 – ELISA geometric mean titer (GMT) from two-week-old chickens post in 
ovo vaccination with rD78GLSNS∆ and 10 days post IBDV challenge. A) SPF 
embryos vaccinated with 5.6 x 103 pfu/egg of the vaccine; B) SPF embryos vaccinated 
with 2.3 x 103 pfu/egg of the vaccine; C) SPF embryos unvaccinated, but challenged at 2 
weeks post in ovo vaccination; D) SPF embryos were neither vaccinated, nor challenged; 
E) broiler embryos vaccinated with 5.6 x 103 pfu/egg; F) broiler embryos unvaccinated, 




The averages of microscopic lesions are shown in Table 8. At 2 weeks post-
vaccination, birds from the control and treatment groups that received either full dose or 
half dose did not show microscopic lesions in the BF. At 10 days post-challenge, SPF 
non-vaccinated birds that were challenged showed severe lymphocyte depletion, 
undulation in the epithelium, intra and interfollicular epithelial cysts, and degeneration of 
follicular structure (Figure 14 A, Table 8 - C). SPF birds that received full dose of the 
vaccine (Figure 14 B) showed a mild degree of B-cell depletion, localized in a few 
follicles. The lesion score for this group was 2.0. SPF birds vaccinated with a half dose of 
the vaccine did not show histopathological lesions in the bursa (Figure 14 C, Table 8 - B). 
The control non-vaccinated, challenged broilers showed bursal lesions. However, they 
were much milder than SPF challenged controls (Figure 14 D, Table 8 - F). In addition, 
broilers that received a full dose of the vaccine showed normal bursae after 10 days post 
IBDV challenge (Figure 14 F, Table 8 - E).
The spleens of SPF non-vaccinated, challenged birds showed hemorrhages and 
lymphocytic depletion. Non-vaccinated broilers that were challenged showed a milder 
but more generalized reduction of lymphocytes throughout the entire organ.  No lesions 
were observed in the spleens from vaccinated groups (data not shown). 
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Figure 14 – Sections of the BF stained by hematoxylin-eosin for histopathological 
examination 10 days post-challenge with IBDV-STC. Eighteen-day-old embryos were 
inoculated with either 5.6 x 103 pfu (full dose) or 2.3 x 103 pfu (half dose) of 
rD78GLSNS∆. A) non-vaccinated, challenged SPF, shows severe lymphocytic necrosis 
and heterophilic inflammation; B) vaccinated (full dose) and challenged SPF birds shows 
lymphocytic depletion (indicated by arrows); C) vaccinated (half dose) and challenged 
SPF shows no visible microscopic lesions; D) non-vaccinated, challenged broiler shows 
lymphocytic necrosis and loss of follicular structure; E) unvaccinated, and non-
challenged control broiler shows no microscopic lesions; F) vaccinated (full dose) and 






IBD in chickens was first described in 1962 (Cosgrove, 1962). IBDV is a 
lymphotropic virus able to cause mainly humoral immunosuppresion in chickens infected 
before three weeks of age (Sharma and Lee, 1983). Efficacy studies with commercial live 
vaccines in ovo against IBDV caused acute clinical signs of the disease when 
administered in a full dose. Additionally, hatchability was severely decreased (Sharma et 
al., 2001). Attempts to administer commercial vaccines in a lower dosage induced less 
mortality, however, microscopic bursal lesions persisted (Lukert and Saif, 1997). In 
addition, since 1980 new subtypes of serotype I, called ‘variant strains’ have been 
isolated in the US (Snyder et al., 1988). Active or passive immunity mediated by 
vaccination with classic strains do not protect against variant strains (Rosenberger et al., 
1985).
In this study, a recombinant live attenuated vaccine that expresses multiple 
neutralizing epitopes of classical and variant strain of IBDV was evaluated in 18-day-old 
SPF and commercial embryos. SPF embryos were injected with a full or half dose of the 
virus through the amniotic cavity. Two weeks post-vaccination, birds were challenged 
with an IBDV-STC strain. Commercial broilers vaccinated with a full dose and SPF 
embryos vaccinated with half dose were fully protected. In addition, no significant 
microscopic bursal lesions were observed in these groups.  On the other hand, SPF birds 
that received a full dose of the vaccine in ovo exhibited microscopic lesions similar to 
unvaccinated, challenged control group.
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No detrimental effects on hatchability with either dosage used were observed. 
However, histopathological results suggested that a higher dose of the vaccine given to 
birds that lack sufficient maternal antibody may still be virulent even though clinical 
signs of IBD were not observed. Our findings agree with previous research in SPF and 
broiler embryos vaccinated with three commercial intermediate vaccines in ovo. 
Microscopic bursal lesions were observed even when half of the recommended dose was 
used (Giambrone et al., 2001). 
In a previous report, microscopic lesions were not observed when a full dose of 
rIBDV live attenuated virus was used to vaccinate two-week-old chickens ocularly (Liu, 
2003). In this study, bursal lesions were observed in SPF birds, lacking maternal 
antibodies that received a full dose of the vaccine when delivered in ovo. At 10 and 15 
days of embryonation, prebursal stem cells are migrating via the blood supply from the 
spleen to the BF (Masteller et al., 1994). Consequently, at eighteen days of incubation, 
when in ovo vaccination occurred, the avian immune system was not fully developed and 
a viral infection that targets this organ may have caused irreversible damage.   
A second aim of this study was to evaluate the efficacy of this chimeric virus as a 
potential vaccine in the presence of maternal antibodies. Commercial broilers were from 
breeder flocks vaccinated with classic and variant strains of IBDV. Vaccinated broilers 
had significant higher antibody titers than non-vaccinated broiler control group at two 
weeks post vaccination. According to Lutticken et al., 1994, these findings indicate that 
the vaccine was able to breakthrough maternal antibody barrier and seroconvert. Similar 
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results were obtained in broilers vaccinated with a chimeric IBDV vaccine 14 days post-
vaccination (Mundt et al., 2003). However in their studies, the challenge using classic 
and variant viruses induced chronic lesions in BF of vaccinated broilers with a chimeric 
virus expressing classic and variant epitopes of GLS and D78 IBDV strains (Mundt et al., 
2003).
On the other hand, despite protection against challenge, vaccinated broilers did 
not show an increased humoral response after challenge, as expected. One possible 
explanation is that the sampling period (10 days after challenge) was too early in order to 
detect an increased antibody response. 
Due to the poor quality of SPF eggs, it would be valuable to repeat this 
experiment in a new set of eggs. However, we had several constraints regarding time, 
facility, and personnel. 
The novelty of this work is its use in ovo to vaccinate commercial broilers in the 
presence of maternal immunity against IBDV. This study suggests the potential use of 
rD78GLSNS∆ as a vaccine candidate for in ovo delivery. This vaccine was shown to be 
safe, highly immunogenic, and protective against STC-IBDV challenge. More studies 
regarding properties of the virus in face of variant strain challenges are necessary.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
6.1. CONCLUSIONS
A typical vaccination program for breeders consists of live vaccines, as well as 
killed vaccines containing classic and antigenic variant viruses. Unfortunately, passive 
immunity is variable and transient. In addition, vaccination with inactivated vaccines is 
laboring, time consuming, expensive, and often inaccurate. Live vaccines used in chicks 
during the first few days of life are not suitable for in ovo use. Therefore, to aid IBDV 
control, we used the well established in ovo technology for vaccine delivery to evaluate 
two new vaccines against IBDV. 
Initially we generated a better in ovo delivery system to be used for DNA 
vaccines. We showed that amniotic cavity results in better transfection rates in a safe 
manner. We also showed that a cationic DNA vaccine adjuvant (PEI - ExGen®) resulted 
in higher plasmid expression when delivered through the amniotic cavity. Microscopic 
examination of several tissues revealed the presence of the reporter gene in many 
different organs, indicating the capacity of the plasmid DNA to transfect several cell 
types. Our findings also show that plasmid DNA was able to generate a humoral immune 
response and partially protect 3 week-old chickens against IBDV challenge. Very little is 
known regarding DNA vaccines for poultry, specially when delivered in ovo.
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Unfortunately, the cost of PEI-ExGen is prohibitive and more research has to be done to 
develop a cost-efficient DNA vaccine for the poultry industry. Interesting and promising 
results are under way using various lipids, and immune estimulators, such as CpGs 
sequences (Wang et al., 2003). Considering that most viral diseases affecting young 
chicks have the respiratory tract as the entry site for virus replication and dissemination, 
it would be interesting to find an adjuvant able to target the plasmid DNA delivery into 
the mucosa of the upper respiratory tract. 
Our IBDV-DNA study showed better protection when followed by an IBDV-
protein boost. VP2 is the most immunogenic protein of IBDV and it has been expressed 
in many different systems. The use of a subunit vaccine consisting of baculovirus 
expressed VP2-VP4-VP3 proteins to boost immunity mounted primarily by a plasmid 
DNA vaccine is novel. It elicited a significantly higher immune response than DNA 
vaccine alone. Thus, protection against challenge was significantly improved. This work 
also suggests the possible use of plasmid DNA vaccine to prime the host immune system, 
followed by a live attenuated vaccine.
Throughout our studies regarding plasmid DNA vaccines, several attempts were 
made to assess cellular immunity after in ovo delivery. Two different ELISA tests were 
used to detect IFN-γ at 7 and 14 days after in ovo vaccination. We were unable to detect 
it by either test, indicating that IFN responses are fast and transient. We also performed 
T-cell proliferation, and macrophage activation (NO) assays and no responses were 
observed.
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Reverse genetic system allowed us to evaluate a tailored vaccine expressing 
multiple neutralizing epitopes of classical and variant strain of IBDV. The in ovo delivery 
of this live attenuated vaccine generated a strong and fully protective immune response in 
chickens challenged at two weeks post-vaccination. 
Many other attenuated IBDV vaccines have been tested for in ovo use. However, 
they cause bursal damage and consequently immunosuppression. Our findings indicate 
that the rIBDV did not affect hatchability or first week survival. In addition, no bursal 
damage or microscopic lesions were observed in broilers. Regarding the maternal 
antibody barrier, we observed that our rIBDV vaccines did not overcome it as 
demonstrated by serology. It is possible that attenuation provided by VP5 deletion did not 
allow the virus to replicate efficiently in high titers due to antibody neutralization. 
6.2. FUTURE WORK
DNA vaccines have shown potential use to protect chickens from different 
pathogens (Oshop et al., 2003, Suarez et al., 2000; Song et al., 2001). Specifically against 
IBDV, DNA vaccines containing VP2 gene or the polyprotein (VP2-VP4-VP3) were 
evaluated (Wu et al., 2002; Fodor et al., 1999). Better results were obtained using VP2-
VP4-VP3 proteins. In order to increase the efficiency of plasmid DNA vaccines against 
IBDV, few approaches were already studied using CpG sequences. Another approach 
would be the use of cytokines, such as interferon to enhance IBDV plasmid DNA vaccine 
responses and protection.
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In Chapter 5, we discussed the potential use of a chimeric vaccine that expresses 
epitopes of variant (GLS) and classic (D78) strains of IBDV. Our challenge studies were 
performed using a USDA standard IBDV challenge strain, STC. We demonstrated that 
vaccinated birds with or without maternal antibodies were fully protected after challenge. 
We also demonstrated that the tailor made chimeric vaccine was able to breakthrough 
maternal immunity against variant and classic strains of IBDV. However, in the future it 
would be of interest to evaluate the efficiency of this marker live attenuated vaccine in 
18-day-old embryos against challenge with a variant strain, such as GLS. In addition, this 
chimeric vaccine should also be evaluated in conjugation with MD vaccines in order to 
expand the usefulness of the in ovo vaccination technology for poultry.  Another control 
group should also be included, consisting of a vaccinated group with D78, a classical 
vaccine against IBDV.
We also recommend few extra samplings in the future experiment in order to 
observe in vivo kinetics of this chimeric construct. For example, we checked for possible 
bursal damage two weeks post-vaccination. It is possible that after two weeks BF had 
already recovered in case the vaccine caused any bursal damage. Few more samplings 
could have been done 1, 3, 7, 10 and 14 days post-vaccination. 
It would be useful to perform this experiment for a longer period in the broilers, 
up to 47 days and include few extra blood samplings to verify antibody responses.     
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